

CURRICULUM VITAE

Michael A. Gorin, M.D.



Last updated: March 4, 2022

Personal Data

2606 Lighthouse Lane
Baltimore, MD 21224
Phone: (305) 721-9515
E-mail: michaelagorin@gmail.com
Web: <https://www.michaelagorin.com>
Twitter: @michael_gorin

Professional Experience

2017–2020 Assistant Professor of Urology, Oncology, Pathology, Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, MD
2020–Present Urologist, Urology Associates & UPMC Western Maryland, Cumberland, MD
2021–Present Clinical Assistant Professor, Department of Urology, University of Pittsburgh School of Medicine, Pittsburgh, PA
2021–Present Adjunct Clinical Assistant Professor, Department of Surgery, Lake Erie College of Osteopathic Medicine, Erie, PA

Education and Training

Undergraduate
2003–2007 B.S. with Distinction in Cell and Molecular Biology, University of Michigan, Ann Arbor, MI

Doctoral/Graduate
2007–2011 M.D. with Distinction in Research, University of Miami Leonard M. Miller School of Medicine, Miami, FL

Postdoctoral
2011–2012 General Surgery Internship, Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD
2012–2017 Urology Residency, Department of Urology, Johns Hopkins University School of Medicine, Baltimore, MD
2017–2019 Fellowship in Endourology and Minimally Invasive Surgery, Johns Hopkins University School of Medicine, Baltimore, MD

Professional Memberships

2011–2019 Resident/Fellow Member, American Urological Association
2017–Present Member, Endourology Society
2019–Present Associate Member, American Urological Association
2020–Present Member, Focal Therapy Society

Certification

2009	USMLE Step I (251)
2011	USMLE Step 2 CK (251)
2011	USMLE Step 2 CS (Pass)
2013	USMLE Step 3 (240)

Boards, Other Specialty Certification

2017	American Board of Urology, Part I
------	-----------------------------------

Medical / Government Licensure

2011–Present	National Provider Identifier Database
2017–Present	Maryland Medical License
2017–Present	Maryland CDS Registration
2017–Present	DEA Controlled Substance Registration
2021–Present	New York Medical License

HONORS & AWARDS

2002	Finalist, Intel International Science and Engineering Fair
2004	Summer Undergraduate Research Fellowship, The Rockefeller University
2007	Graduation with Distinction, University of Michigan
2008	Best University of Miami Presentation (Sponsored by the American Medical Association Foundation), 34 th Annual Eastern-Atlantic Student Research Forum
2008	American Cancer Society Summer Research Fellowship, University of Miami Sylvester Comprehensive Cancer Center
2009	Iron Arrow Honor Society, University of Miami
2010	Drs. Carl and Barbara Alving Endowed Award for Outstanding Biomedical Research, University of Miami Miller School of Medicine
2010	Distinction in Research, University of Miami Miller School of Medicine
2010	Alpha Omega Alpha (ΑΩΑ) Honor Medical Society, University of Miami Miller School of Medicine
2010	John K. Robinson Travel Grant, Medical Alumni Association, University of Miami Miller School of Medicine
2011	Honorable Mention in Surgery, 37 th Annual Eastern-Atlantic Student Research Forum
2011	Department of Medical Education Unsung Hero Award, University of Miami Miller School of Medicine
2012	Highest Departmental Urology In-service Examination Score (93 rd Percentile)
2013	Highest Departmental Urology In-service Examination Score (94 th Percentile)
2014	Certificate of Reviewing Excellence, <i>Urology</i>
2015	Best Clinical Research Poster, 2015 Scientific Session of the National Kidney Foundation of Maryland
2015	Best Paper Award, Department of Urology Academic Session at the 2015 Johns Hopkins Medical and Surgical Association Biennial Meeting
2015	<i>Nature Reviews Urology</i> 2016 Annual Cover Image Contest Winner
2015	Best Poster Award, 16 th Annual Meeting of the Society of Urologic Oncology
2015	Highest Departmental Urology In-service Examination Score (100 th Percentile)
2016	Frank L. Coulson Jr. Resident Clinical Excellence Award, Johns Hopkins University School of Medicine
2016	Best Paper Award, 31 st Annual Meeting of the Engineering & Urology Society
2016	Resident Research Award, Annual Residency Retreat, The James Buchanan Brady Urological Institute
2016	<i>Urology</i> Top Reviewers, 2015
2017	Johns Hopkins House Staff Council Resident Appreciation Award
2017	Best Reviewer Award, 32 nd Annual Meeting of the Engineering & Urology Society
2017	<i>Urology</i> Top Reviewers, 2016

- 2018 *Urology* Top Reviewers, 2017
- 2018 3rd Place, Early-Career Investigators Showcase at the American Urological Association 2018 Annual Meeting
- 2018 William F. Rienhoff, Jr., M.D. Scholar Award, Johns Hopkins University School of Medicine
- 2018 Star Reviewer for *Urologic Oncology: Seminars and Original Investigation*

SCHOLARLY ACTIVITY

Publications

h-index = 45, citations = 7,420

Google Scholar: <https://scholar.google.com/citations?user=hOWsYWwAAAAAJ&hl=en>

PubMed: <https://pubmed.ncbi.nlm.nih.gov/?term=gorin+ma>

Original Research

1. Elstrodt F, Hollestelle A, Nagel JH, **Gorin M**, Wasielewski M, van den Ouweland A, Merajver SD, Ethier SP, Schutte M. BRCA1 mutation analysis of 41 human breast cancer cell lines reveals three new deleterious mutants. *Cancer Res* 2006; 66(1): 41-5.
2. Bao LW, **Gorin MA**, Zhang M, Ventura AC, Pomerantz WC, Merajver SD, Teknos TN, Mapp AK, Pan Q. Preclinical development of a bifunctional cancer cell homing, PKCε inhibitory peptide for the treatment of head and neck cancer. *Cancer Res* 2009; 69(14): 5829-34.
3. Khan GN, **Gorin MA**, Rosenthal D, Pan Q, Bao LW, Wu ZF, Newman RA, Pawlus AD, Yang P, Lansky EP, Merajver SD. Pomegranate fruit extract impairs invasion and motility in human breast cancer. *Integr Cancer Ther* 2009; 8(3): 242-53.
4. Iniesta MD, **Gorin MA**, Chien LC, Thomas SM, Douglas JD, Milliron KJ, Merajver SD. Absence of 1100delC CHEK2 mutation in families with hereditary breast cancer in North America. *Cancer Genet Cytogenet* 2010; 202(2): 136-40.
5. **Gorin MA**, Manoharan M, Shah G, Eldefrawy A, Soloway MS. Salvage open radical prostatectomy after failed radiation therapy: a single center experience. *Cent European J Urol* 2011; 64(3): 144-7.
6. **Gorin MA**, Santos Cortes JA, Kyle CC, Carey RI, Bird VG. Initial clinical experience with use of ureteral access sheaths in the diagnosis and treatment of upper tract urothelial carcinoma. *Urology* 2011; 78(3): 523-7.
7. Shirodkar SP, **Gorin MA**, Sageshima J, Bird VG, Martinez JM, Guerra G, Zarak A, Chen L, Burke GW, Ciancio G. Technical modification for laparoscopic donor nephrectomy to minimize testicular pain: a complication with significant morbidity. *Am J Transplant* 2011; 11(5): 1031-4.
8. Salas N, **Gorin MA**, Gorbatiy V, Castle SM, Bird VG, Leveillee RJ. Laparoendoscopic single site nephrectomy with the SPIDER surgical system: engineering advancements tested in a porcine model. *J Endourol* 2011; 25(5): 739-42.
9. **Gorin MA**, Soloway CT, Eldefrawy A, Soloway MS. Factors that influence patient enrollment in active surveillance for low-risk prostate cancer. *Urology* 2011; 77(3): 588-91.
10. **Gorin MA**, Ramanathan R, Leveillee RJ. Laparoscopic techniques applied to open surgery: sliding-clip renorrhaphy. *Urology* 2011; 77(3): 751-3.
11. Garcia-Roig M, **Gorin MA**, Castellian M, Ciancio G. OMNEX surgical sealant in the extracorporeal repair of renal artery aneurysms. *Ann Vasc Surg* 2011; 25(8): 1141.e5-8.
12. Landy DC, **Gorin MA**, O'Connell MT. Student Led Rural Health Fairs: Attempting to improve medical education and access to healthcare. *South Med J* 2011; 104(8): 598-603.
13. **Gorin MA**, Shirodkar SP, Young E, Ciancio G. En bloc mobilization of the spleen, pancreas and colon during hand-assisted laparoscopic left donor nephrectomy. *Eur Urol* 2011; 60(3): 601-2.
14. **Gorin MA**, Garcia-Roig M, Shirodkar SP, Gonzalez J, Ciancio G. Modified surgical technique for the management of renal cell carcinoma with level I or II tumor thrombus. *Urology* 2012; 79(2): 478-81.

15. **Gorin MA**, Gahan J, Antebi E, Carey RI, Bird VG. Laparoscopic-guided radiofrequency ablation is safe for the treatment of enhancing renal masses among patients prescribed antithrombotic agents. *Clin Appl Thromb Hemost* 2012; 18(1): 35-9.
16. Castle SM, Gorbatiy V, Salas N, **Gorin MA**, Landman J, Leveillee RJ. Development and evaluation of a novel cadaveric model for performance of image-guided percutaneous renal tumor ablation. *J Surg Educ* 2012; 69(1): 30-3.
17. **Gorin MA**, Eldefrawy A, Manoharan M, Soloway MS. Oncologic outcomes following radical prostatectomy with intraoperative cell salvage. *World J Urol* 2012; 30(3): 379-83.
18. **Gorin MA**, Eldefrawy A, Ekwenna O, Soloway MS. Active surveillance for low-risk prostate cancer: knowledge, acceptance and practice among urologists. *Prostate Cancer Prostatic Dis* 2012; 15(2): 177-81.
19. Soloway MS, Iremashvili V, **Gorin MA**, Eldefrawy A, Satyanarayana R, Manoharan M. Surgical margin status does not affect overall survival following radical prostatectomy: a single institution experience with expectant management. *Can J Urol* 2012; 19(3): 6280-6.
20. Landy DC, **Gorin MA**, Egusquiza JD, Weiss J, O'Connell MT. Medical student attitudes before and after participating in rural health fairs. *J Res Med Sci* 2012; 17(3): 298-303.
21. Ayyathurai R, Garcia-Roig M, **Gorin MA**, González J, Manoharan M, Kava BR, Soloway MS, Ciancio G. Bland thrombus association with tumor thrombus in renal cell carcinoma: analysis of surgical significance and role of inferior vena caval interruption. *BJU Int* 2012; 110(11 Pt B): E449-55.
22. Joshi S, **Gorin MA**, Ayyathurai R, Ciancio G. Development of a surgical safety checklist for the performance of radical nephrectomy and tumor thrombectomy. *Patient Saf Surg* 2012; 6(1): 27.
23. Garcia-Roig M, **Gorin MA**, Parra-Herran C, Garcia-Buitrago M, Kava BR, Jorda M, Soloway MS, Manoharan M, Ciancio G. Pathologic evaluation of non-neoplastic renal parenchyma in partial nephrectomy specimens. *World J Urol* 2013; 31(4): 835-9.
24. Castle SM, **Gorin MA**, Gorbatiy V, Leveillee RJ. Preoperative patient counseling for diagnostic renal biopsy and complications with renal radiofrequency ablation. *World J Urol* 2013; 31(5): 1105-10.
25. **Gorin MA**, Garcia-Roig M, Garcia-Buitrago M, Parra-Herran C, Jorda M, Ciancio G. Atherosclerosis within the non-neoplastic margin of partial nephrectomy specimens: implications for medical management. *World J Urol* 2013; 31(6): 1531-4.
26. Landy DC, **Gorin MA**, Rudock RJ, O'Connell MT. Increasing access to cholesterol screening in rural communities catalyzes cardiovascular disease prevention. *J Rural Health* 2013; 29(4): 360-7.
27. **Gorin MA**, Mullins JK, Pierorazio PM, Jayram G, Allaf ME. Increased intra-abdominal fat predicts perioperative complications following minimally invasive partial nephrectomy. *Urology* 2013; 81(6): 1225-30.
28. Bivalacqua TJ, Pierorazio PM, **Gorin MA**, Allaf ME, Carter HB, Walsh PC. Anatomical extent of pelvic lymph node dissection: impact on long-term cancer-specific outcomes in men with positive lymph nodes at time of radical prostatectomy. *Urology* 2013; 82(3): 635-8.
29. Pierorazio PM, **Gorin MA**, Ross AE, Feng Z, Trock BJ, Schaeffer EM, Han M, Epstein JI, Partin AW, Walsh PC, Bivalacqua TJ. Pathological and oncologic outcomes for men with positive lymph nodes at radical prostatectomy: the Johns Hopkins Hospital 30-year experience. *Prostate* 2013; 73(15): 1673-80.
30. Khalifeh A, Kaouk JH, Bhayani S, Rogers C, Stifelman M, Tanagho YS, Kumar R, **Gorin MA**, Sivarajan G, Samarasekera D, Allaf ME. Positive surgical margins in robot assisted partial nephrectomy: a multi-institutional analysis of oncological outcomes (leave no tumor behind). *J Urol* 2013; 190(5): 1674-9.
31. **Gorin MA**, Ball MW, Pierorazio PM, Tanagho YS, Bhayani SB, Kaouk JH, Rogers CG, Stifelman MD, Khalifeh A, Kumar R, Sivarajan G, Allaf ME. Outcomes and predictors of clinical T1 to pathologic T3a tumor upstaging following robotic partial nephrectomy: a multi-institutional analysis. *J Urol* 2013; 190(5): 1907-11.
32. Patel HD, Kates M, Pierorazio PM, Hyams ES, **Gorin MA**, Ball MW, Bhayani SB, Hui X, Thompson CB, Allaf ME. Survival after diagnosis of localized T1a kidney cancer: current population-based practice of surgery and nonsurgical management. *Urology* 2014; 83(1): 126-33.
33. Kates M, **Gorin MA**, Deibert CM, Pierorazio PM, Schoenberg MP, McKiernan JM, Bivalacqua TJ. In-hospital death and hospital-acquired complications among patients undergoing partial cystectomy for bladder cancer in the United States. *Urol Oncol* 2014; 32(1): 53.e9-53.e14.

34. Reese AC, Ball MW, Gandhi N, **Gorin MA**, Netto GJ, Bivalacqua TJ, Schoenberg MP. The utility of an extensive postchemotherapy staging evaluation in patients receiving neoadjuvant chemotherapy for bladder cancer. *Urology* 2014; 84(2): 358-63.
35. Kumar RK, Sammon JD, Kaczmarek BF, Khalifeh A, **Gorin MA**, Sivarajan G, Tanagho YS, Bhayani SB, Stifelman MD, Allaf ME, Kaouk JH, Rogers CG. Robot-assisted partial nephrectomy in patients with baseline chronic kidney disease: a multi-institutional propensity score-matched analysis. *Eur Urol* 2014; 65(6): 1205-10.
36. **Gorin MA**, Chalfin HJ, Epstein JI, Feng Z, Partin AW, Trock BJ. Predicting the risk of non-organ-confined prostate cancer when perineural invasion is found on biopsy. *Urology* 2014; 83(5): 1117-21.
37. Garcia-Roig M, Castellan M, González J, **Gorin MA**, Cruz-Diaz O, Labbie A, Gosalbez R, Sigmoid vaginoplasty with a modified single-Monti tube: a pediatric case series. *J Urol* 2014; 191(5 Suppl): 1537-42.
38. **Gorin MA**, Kates M, Mullins JK, Pierorazio PM, Matlaga BR, Schoenberg MP, Bivalacqua TJ. Impact of hospital volume on perioperative outcomes and costs of radical cystectomy: analysis of the Maryland Health Services Cost Review Commission database. *Can J Urol* 2014; 21(1): 7102-7.
39. Harris KT, Ball MW, **Gorin MA**, Curtiss KM, Pierorazio PM, Allaf M. Transperitoneal robot-assisted partial nephrectomy: a comparison of posterior and anterior renal masses. *Journal Endourol* 2014; 28(6): 655-9.
40. Reese AC, Johnson PT, **Gorin MA**, Pierorazio PM, Allaf MR, Fishman EK, Netto GJ, Pavlovich CP. Radiographic findings and pathological characteristics of complex renal cysts. *Urol Oncol* 2014; 32(7): 1010-6.
41. Kern AJM, Inouye B, Ko JS, **Gorin MA**, Allaf ME, Goldstein S, DiCarlo HN, Shah BB, Wang MH. Impact of nephrectomy on long-term renal function in non-syndromic children treated for unifocal Wilms tumor. *J Pediatr Urol* 2014; 10(4): 662-6.
42. Patel HD, Kates M, Pierorazio PM, **Gorin MA**, Jayram G, Ball MW, Hyams ES, Allaf ME. Comorbidities and causes of death in the management of localized T1a kidney cancer. *Int J Urol* 2014; 21(11): 1086-92.
43. Curtiss KM, Ball MW, **Gorin MA**, Harris KT, Pierorazio PM, Allaf ME. Perioperative outcomes of robotic partial nephrectomy for intrarenal tumors. *J Endourol* 2015; 29(3): 293-6.
44. Max Kates M, Ball MW, Patel HD, **Gorin MA**, Pierorazio PM, Allaf ME. The financial impact of robotic technology for partial and radical nephrectomy. *J Endourol* 2015; 29(3): 317-22.
45. Ball MW, Bezerra SM, **Gorin MA**, Cowan M, Pavlovich CP, Pierorazio PM, Netto GJ, Allaf ME. Grade heterogeneity in small renal masses: potential implications for renal mass biopsy. *J Urol* 2015; 193(1): 36-40.
46. Rowe SP, **Gorin MA**, Gordetsky J, Ball MW, Pierorazio PM, Higuchi T, Epstein JI, Allaf, Javadi MS. Initial experience using ^{99m}Tc-sestamibi SPECT/CT for the differentiation of oncocytoma from renal cell carcinoma. *Clin Nucl Med* 2015; 40(4): 309-13.
47. Ball MW, **Gorin MA**, Jayram G, Pierorazio PM, Allaf ME. Robot-assisted radical nephrectomy with inferior vena cava tumor thrombectomy: technique and initial outcomes. *Can J Urol* 2015; 22(1): 7666-70.
48. **Gorin MA**, Ball MW, Pierorazio PM, Argani P, Allaf ME. Partial nephrectomy for the treatment of translocation renal cell carcinoma. *Clin Genitourin Cancer* 2015; 13(3) e199-201.
49. Ball MW, **Gorin MA**, Bhayani SB, Rogers CG, Stifelman MD, Kaouk JH, Zargar H, Marshall S, Larson JA, Rahbar HM, Trock BJ, Pierorazio, Allaf ME. Preoperative predictors of malignancy and unfavorable pathology for clinical T1a tumors treated with partial nephrectomy: a multi-institutional analysis. *Urol Oncol* 2015; 33(3): 112.e9-14.
50. Pierorazio PM, Johnson MH, Ball MW, **Gorin MA**, Trock BJ, Chang P, Wagner AA, McKiernan JM, Allaf ME. Five-year analysis of a multi-institutional prospective clinical trial of delayed intervention and surveillance for small renal masses: the DISSRM registry. *Eur Urol* 2015; 68(3): 408-15.
51. Harris KT, Ball MW, **Gorin MA**, Allaf ME, Pierorazio PM. Outcomes of partial nephrectomy in patients who meet percutaneous ablation criteria. *Cent European J Urol* 2015; 68(2): 132-6.
52. Ludwig W, **Gorin MA**, Ball MW, Schaeffer EM, Han M, Allaf ME. Instrument life for robot assisted laparoscopic radical prostatectomy and partial nephrectomy: are ten lives for most instruments justified? *Urology* 2015; 86(5): 942-6.
53. **Gorin MA**, Rowe SP, Allaf ME, Argani P. Angiomyolipoma with epithelial cysts: add one to the differential of cystic renal lesions. *Int J Urol* 2015; 22(11): 1081-2.

54. Rowe SP, **Gorin MA**, Hammers HJ, Javadi MS, Hawasli H, Szabo Z, Cho SY, Pomper MG, Allaf ME. Imaging of metastatic clear cell renal cell carcinoma with PSMA-Targeted ¹⁸F-DCFPyL PET/CT. *Ann Nucl Med* 2015; 29(10): 877-82.
55. Yang X, Minn I, Rowe SP, Banerjee SR, **Gorin MA**, Brummet M, Lee HS, Koo SM, Sysa-Shah P, Mease RC, Nimmagadda S, Allaf ME, Pomper MG. Imaging of carbonic anhydrase IX with an ¹¹¹In-labeled dual-motif inhibitor. *Oncotarget* 2015; 6(32): 33733-42.
56. Gordetsky J, **Gorin MA**, Canner J, Ball MW, Pierorazio PM, Allaf ME, Epstein JI. Frozen section during partial nephrectomy: does it predict positive margins? *BJU Int* 2015; 116(6): 868-72.
57. Harris KT, **Gorin MA**, Ball MW, Pierorazio PM, Allaf ME. A comparative analysis of robotic vs laparoscopic retroperitoneal lymph node dissection for testicular cancer. *BJU Int* 2015; 116(6): 920-3.
58. Althumairi AA, Canner JK, **Gorin MA**, Fang SH, Gearhart SL, Wick EC, Safar B, Bivalacqua TJ, Efron JE. Reduction of costs for pelvic exenteration performed by high volume surgeons: analysis of the Maryland health service cost review commission database. *Am Surg* 2016; 82(1): 46-52.
59. Cheung KJ, Padmanaban V, Silvestri V, Schipper K, Cohen JD, Fairchild AN, **Gorin MA**, Verdone JE, Pienta KJ, Bader JS, Ewald AJ. Polyclonal breast cancer metastases arise from collective dissemination of keratin 14 expressing tumor cell clusters. *Proc Natl Acad Sci USA* 2016; 113(7): E854-63.
60. **Gorin MA**, Rowe SP, Baras A, Solnes L, Ball MW, Pierorazio PM, Pavlovich CP, Epstein JI, Javadi MS, Allaf ME. Prospective evaluation of ^{99m}Tc-sestamibi SPECT/CT for the diagnosis of renal oncocytomas and hybrid oncocytic/chromophobe tumors. *Eur Urol* 2016; 69(3): 413-6.
61. Gogoi P, Sepehri S, Zhou Y, **Gorin MA**, Paolillo C, Capoluongo E, Gleason K, Payne A, Boniface B, Fortina P, Cristofanilli M, Morgan TM, Pienta KJ, Handique K, Wang Y. Development of an automated and sensitive microfluidic device for capturing and characterizing circulating tumor cells (CTCs) from clinical blood samples. *PLoS ONE* 2016; 11(1): e0147400.
62. Ball MW, **Gorin MA**, Harris KT, Curtiss KM, Netto GJ, Pavlovich CP, Pierorazio PM, Allaf ME. Extent of renal vein invasion influences prognosis in patients with renal cell carcinoma. *BJU Int* 2016; 118(1): 112-7.
63. Bhatnagar A, Rowe SP, **Gorin MA**, Pomper MG, Fishman EK, Allaf ME. Computed tomography appearance of renal hybrid oncocytic/chromophobe tumors. *J Comput Assist Tomogr* 2016; 40(4): 513-6.
64. Helmers MR, Ball MW, **Gorin MA**, Pierorazio PM, Allaf ME. Robotic versus laparoscopic radical nephrectomy: comparative analysis and cost considerations. *Can J Urol* 2016; 23(5): 8435-40.
65. Ball MW, **Gorin MA**, Guner G, Pierorazio PM, Netto G, Paller CJ, Hammers HJ, Diaz LA, Allaf ME. Circulating tumor DNA as a marker of therapeutic response in patients with renal cell carcinoma: a pilot study. *Clin Genitourin Cancer* 2016; 14(5): e515-20.
66. Minn I, Koo SM, Lee HS, Brummet M, Rowe SP, **Gorin MA**, Sysa-Shah P, Lewis WD, Ahn HH, Wang Y, Banerjee SR, Mease RC, Nimmagadda S, Allaf ME, Pomper MG, Yang X. [⁶⁴Cu]-XYIMSR-06: a dual-motif CAIX ligand for PET imaging of clear cell renal cell carcinoma. *Oncotarget* 2016; 7: 56471-9.
67. Valkenburg KC, Amend SR, Verdone JE, van der Toom EE, Hernandez JR, **Gorin MA**, Pienta KJ. A simple selection-free method for detecting disseminated tumor cells (DTCs) in murine bone marrow. *Oncotarget* 2016; 7: 69794-803.
68. Patel HD, **Gorin MA**, Gupta N, Kates M, Johnson MH, Pierorazio PM, Allaf ME. Mortality trends and the impact of lymphadenectomy on survival for renal cell carcinoma patients with distant metastasis. *Can Urol Assoc J* 2016; 10: 389-395.
69. van der Toom EE, Verdone JE, Jun C, Petrisor D, Lim S, de la Rosette JJ, de Reijke TM, **Gorin MA**, Pienta KJ, Stoianovici D. A surface tension magnetophoretic device for rare cell isolation and characterization. *Med Oncol* 2017; 34: 22.
70. **Gorin MA**, Rowe SP, Hooper JE, Kates M, Hammers HJ, Szabo Z, Pomper MG, Allaf ME. PSMA-targeted ¹⁸F-DCFPyL PET/CT imaging of clear cell renal cell carcinoma: results from a rapid autopsy. *Eur Urol* 2017; 71: 145-6.
71. Pearce SM, Golan S, **Gorin MA**, Luckenbaugh AN, Williams SB, Ward JF, Montgomery JS, Hafez KS, Weizer AZ, Pierorazio PM, Allaf ME, Eggener SE. Safety and early oncologic effectiveness of primary robotic retroperitoneal lymph node dissection for nonseminomatous germ cell testicular cancer. *Eur Urol* 2017; 71: 476-482.
72. An JY, Ball MW, **Gorin MA**, Hong JJ, Johnson MH, Pavlovich CP, Allaf ME, Pierorazio PM. Partial vs. radical nephrectomy for T1-T2 renal masses in the elderly: comparison of complications, renal function, and oncologic outcomes. *Urology* 2017; 100: 151-157.

73. Li X, Rowe SP, Leal JP, **Gorin MA**, Allaf ME, Ross AE, Pienta KJ, Lodge MA, Pomper MG. Quantitative parameters in PSMA-targeted PET Imaging with ¹⁸F-DCFPyL: variability in normal organ uptake. *J Nucl Med* 2017; 58: 942-946.
74. Patel HD, Druskin SC, Rowe SP, Pierorazio PM, **Gorin MA**, Allaf ME. Surgical histopathology for suspected oncocytoma on renal mass biopsy: a systematic review and meta-analysis. *BJU Int* 2017; 119: 661-666.
75. Sheikhabaehi S, Jones CS, Porter KK, Rowe SP, **Gorin MA**, Baras AS, Pierorazio PM, Ball MW, Higuchi T, Johnson PT, Solnes LB, Epstein JI, Allaf ME, Javadi MS. Defining the added value of ^{99m}Tc-MIBI SPECT/CT to conventional cross-sectional imaging in the characterization of enhancing solid renal masses. *Clin Nucl Med* 2017; 42: e188-e193.
76. Chalfin HJ, Verdone JE, van der Toom EE, Glavaris S, **Gorin MA**, Pienta KJ. Nucleolin staining may aid in the identification of circulating prostate cancer cells. *Clin Genitourin Cancer* 2017; 15: e477-e481.
77. **Gorin MA**, Marashdeh W, Ross AE, Allaf ME, Pienta KJ, Pomper MG, Rowe SP. Uptake of the prostate-specific membrane antigen-targeted PET radiotracer ¹⁸F-DCFPyL in elastofibroma dorsi. *Nucl Med Commun* 2017; 38(9): 795-798.
78. Ball MW, **Gorin MA**, Drake CG, Hammers HJ, Allaf ME. The landscape of whole-genome alterations and pathologic features in genitourinary malignancies: an analysis of the cancer genome atlas. *Eur Urology Focus* 2017; 3(6): 584-589.
79. Kostibas MP, Arora V, **Gorin MA**, Ball MW, Pierorazio PM, Allaf ME, Nyhan D, Brady MB. Defining the role of intraoperative transesophageal echocardiography during radical nephrectomy with inferior vena cava tumor thrombectomy for renal cell carcinoma. *Urology* 2017; 107: 161-165.
80. Werner RA, Sheikhabaehi S, Jones KM, Javadi MS, Solnes LB, Ross AE, Allaf ME, Pienta KJ, Lapa C, Buck AK, Higuchi T, Pomper MG, **Gorin MA**, Rowe SP. Patterns of uptake of prostate-specific membrane antigen (PSMA)-targeted ¹⁸F-DCFPyL in peripheral ganglia. *Ann Nucl Med* 2017; 31(9): 696-702.
81. Uzosike AC, Patel HD, Alam R, Schwen ZR, Gupta M, **Gorin MA**, Johnson MH, Gausepohl H, Riffon MF, Trock BJ, Chang P, Wagner AA, McKiernan JM, Allaf ME, Pierorazio PM. Growth kinetics of small renal masses on active surveillance: variability and results from the DISSRM registry. *J Urol* 2018; 199(3): 641-48.
82. **Gorin MA**, Rowe SP, Patel HD, Vidal I, Mana-Ay M, Javadi MS, Solnes LB, Ross AE, Schaeffer EM, Bivalacqua TJ, Partin AW, Pienta KJ, Szabo Z, De Marzo AM, Pomper MG, Allaf ME. Prostate specific membrane antigen targeted ¹⁸F-DCFPyL positron emission tomography/computerized tomography for the preoperative staging of high risk prostate cancer: results of a prospective, phase II, single center study. *J Urol* 2018; 199(1): 126-132
83. Srivastava A, Patel HD, Joice GA, Semerjian A, **Gorin MA**, Johnson MH, Allaf ME, Pierorazio PM. Incidence of T3a up-staging and survival after partial nephrectomy: Size-stratified rates and implications for prognosis. *Urol Oncol* 2018; 36(1): 12.e7-12.e13.
84. Rowe SP*, **Gorin MA***, Solnes LB, Ball MW, Choudhary A, Pierorazio PM, Epstein JI, Javadi MS, Allaf ME, Baras AS. Correlation of ^{99m}Tc-sestamibi uptake in renal masses with mitochondrial content and multi-drug resistance pump expression. *EJNMMI Res* 2017; 7(1): 80. *Contributed equally to this work.
85. Jang A, Patel HD, Riffon M, **Gorin MA**, Semerjian A, Johnson MH, Allaf ME, Pierorazio PM. Multiple growth periods predict unfavorable pathology in patients with small renal masses. *BJU Int* 2018; 121(5): 732-736.
86. Semerjian A, Milbar N, Kates M, **Gorin MA**, Patel HD, Chalfin HJ, Frank SM, Wu CL, Yang WW, Hobson D, Robertson L, Wick E, Schoenberg MP, Pierorazio PM, Johnson MH, Stimson CJ, Bivalacqua TJ. Hospital charges and length of stay following radical cystectomy in the ERAS era. *Urology* 2018; 111: 86-91.
87. Campbell SP, Baras AS, Ball MW, Kates M, Hahn NM, Bivalacqua TJ, Johnson MH, Pomper MG, Allaf ME, Rowe SP, **Gorin MA**. Low levels of PSMA expression limit the utility of ¹⁸F-DCFPyL PET/CT for imaging urothelial carcinoma. *Ann Nucl Med* 2018; 32(1): 69-74
88. Jones KM, Solnes LB, Rowe SP, **Gorin MA**, Sheikhabaehi S, Fung G, Frey EC, Allaf ME, Du Y, Javadi MS. Use of quantitative SPECT/CT reconstruction in ^{99m}Tc-sestamibi imaging of patients with renal masses. *Ann Nucl Med* 2018; 32(2): 87-93.

89. Ludwig WW, Wobker SE, Ball MW, Zysk AM, Yemul KS, Pierorazio PM, **Gorin MA**, Allaf ME. Margin assessment in renal surgery using a handheld optical coherence tomography probe. *Urology* 2018; 113: 241-5.
90. Chalfin HJ, Glavaris SA, Malihi PD, Sperger JM, **Gorin MA**, Lu C, Goodwin CR, Chen Y, Caruso EA, Dumpit R, Kuhn P, Lang JM, Nelson PS, Luo J, Pienta KJ. Prostate cancer disseminated tumor cells are rarely detected in the bone marrow of localized patients undergoing radical prostatectomy across multiple rare cell detection platforms. *J Urol* 2018; 199(6): 1494-1501.
91. Meyer AR, Joice GA, Schwen ZR, Partin AW, Allaf ME, **Gorin MA**. Initial experience performing in-office ultrasound-guided transperineal prostate biopsy under local anesthesia using the PrecisionPoint Transperineal Access System. *Urology* 2018; 115: 8-13.
92. Chalfin HJ, Kates M, van der Toom EE, Glavaris S, Verdone JE, Hahn NM, Pienta KJ, Bivalacqua TJ, **Gorin MA**. Characterization of urothelial cancer circulating tumor cells with a novel selection-free method. *Urology* 2018; 115: 82-86.
93. Rowe SP, **Gorin MA**, Allaf ME, Johnson PT, Fishman EK. Photorealistic 3D cinematic rendering of clear cell renal cell carcinoma from volumetric CT data. *Urology* 2018; 115: e3-e5.
94. Rowe SP, Meyer AR, **Gorin MA**, Johnson PT, Fishman EK. 3D CT of renal pathology: initial experience with cinematic rendering. *Abdom Radiol (NY)* 2018; 43(12): 3445-3455.
95. Werner RA, Bundschuh RA, Bundschuh L, Javadi MS, Leal JP, Higuchi T, Pienta KJ, Buck AK, Pomper MG, **Gorin MA**, Lapa C, Rowe SP. Interobserver agreement for the standardized reporting system PSMA-RADS 1.0 on ¹⁸F-DCFPyL PET/CT Imaging. *J Nucl Med* 2018; 59(12): 1857-1864.
96. Alam R, Patel HD, Osumah T, Srivastava A, **Gorin MA**, Johnson MH, Trock BJ, Chang P, Wagner AA, McKiernan JM, Allaf ME, Pierorazio PM. Comparative effectiveness of management options for patients with small renal masses: a prospective cohort study. *BJU Int* 2019; 123(1):42-50.
97. Gupta M, Alam R, Patel HD, Semerjian A, **Gorin MA**, Johnson MH, Chang P, Wagner AA, McKiernan JM, Allaf ME, Pierorazio PM. Use of delayed intervention for small renal masses initially managed with active surveillance. *Urol Oncol* 2019; 37(1):18-25.
98. Ziembra JB, Gurnani R, Ludwig WW, **Gorin MA**, Asplin J, Matlaga BR. Individual renal unit urine sampling to identify unilateral metabolic defects. *Clin Nephrol* 2019; 91:87-94.
99. Sotimehin AE, Patel HD, Alam R, **Gorin MA**, Johnson MH, Chang P, Wagner AA, McKiernan JM, Allaf ME, Pierorazio PM. Selecting patients with small renal masses for active surveillance: a domain-based score from a prospective cohort study. *J Urol* 2019; 201: 886-892.
100. Yin Y, Werner RA, Higuchi T, Lapa C, Pienta KJ, Pomper MG, **Gorin MA**, Rowe SP. Follow-up of lesions with equivocal radiotracer uptake on PSMA-targeted PET in patients with prostate cancer: predictive values of the PSMA-RADS-3A and PSMA-RADS-3B categories. *J Nucl Med* 2019; 60(4): 511-516.
101. Yin Y, Campbell SP, Markowski MC, Pierorazio PM, Pomper MG, Allaf ME, Rowe SP, **Gorin MA**. Inconsistent detection of sites of metastatic non-clear cell renal cell carcinoma with PSMA-targeted [¹⁸F]DCFPyL PET/CT. *Mol Imaging Biol* 2019; 21(3): 567-573.
102. Alshak MN, Gross MD, Shoag JE, Laviana AA, **Gorin MA**, Sedrakyan A, Hu JC. Data on the quality and methods of studies reporting healthcare costs of post-prostate biopsy sepsis. *Data Brief* 2019; 25: 104307.
103. Gupta N, Bivalacqua TJ, Han M, **Gorin MA**, Challacombe BJ, Partin AW, Mamawala MK. Evaluating the impact of length of time from diagnosis to surgery in patients with unfavourable intermediate-risk to very-high-risk clinically localised prostate cancer. *BJU Int* 2019; 124(2): 268-274.
104. Meyer AR, Carducci MA, Denmeade SR, Markowski MC, Pomper MG, Pierorazio PM, Allaf ME, Rowe SP, **Gorin MA**. Improved identification of patients with oligometastatic clear cell renal cell carcinoma with PSMA-targeted ¹⁸F-DCFPyL PET/CT. *Ann Nucl Med* 2019; 33(8):617-623.
105. Gross MD, Alshak MN, Shoag JE, Laviana AA, **Gorin MA**, Sedrakyan A, Hu JC. Healthcare costs of post-prostate biopsy sepsis. *Urology* 2019; 133: 11-15.
106. Zimmerman ME, Meyer AR, Carter HB, Allaf ME, **Gorin MA**. In-office transperineal prostate biopsy using biplanar ultrasound guidance: a step-by-step guide. *Urology* 2019; 133: 247.
107. Rowe SP, Chu LC, Meyer AR, **Gorin MA**, Fishman EK. The application of cinematic rendering to CT evaluation of upper tract urothelial tumors: principles and practice. *Abdom Radiol (NY)* 2019; 44 (12), 3886-3892.

108. Patel NA, Sedrakyan A, Bianco F, Etzioni R, **Gorin MA**, Hsu WC, Mao J, Nguyen PL, Schaeffer E, Shoag J, Vickers A, Hu JC. Definitive and sustained increase in prostate cancer metastases in the United States. *Urol Oncol* 2019; 37(12): 988-990.
109. Cheaib JG, Patel HD, Johnson MH, **Gorin MA**, Haut ER, Canner JK, Allaf ME, Pierorazio PM. Stage-specific conditional survival in renal cell carcinoma after nephrectomy. *Urol Oncol* 2020; 38(1): 6.e1-6.e7.
110. Srivastava A, Patel HD, Gupta M, Joice GA, Schwen Z, Alam R, **Gorin MA**, Johnson MH, Trock BJ, Chang P, Wagner AA, McKiernan JM, Allaf ME, Pierorazio PM. The incidence, predictors, and survival of disappearing small renal masses on active surveillance. *Urol Oncol* 2020; 38(2): 42.e1-42.e6.
111. Rowe SP, Campbell SP, Mana-Ay M, Szabo Z, Allaf ME, Pienta KJ, Pomper MG, Ross AE, **Gorin MA**. Prospective evaluation of PSMA-targeted ¹⁸F-DCFPyL PET/CT in men with biochemical failure after radical prostatectomy for prostate cancer. *J Nucl Med* 2020; 61(1): 58-61.
112. Rowe SP, Li X, Trock BJ, Werner RA, Frey SM, DiGianvittorio M, Bleiler K, Reyes DK, Abdallah R, Pienta KJ, **Gorin MA**, Pomper MG. Prospective Comparison of PET imaging with PSMA-targeted ¹⁸F-DCFPyL versus Na¹⁸F for bone lesion detection in patients with metastatic prostate cancer. *J Nucl Med* 2020; 61(2): 183-188.
113. Hrinivich WT, Phillips R, Da Silva AJ, Radwan N, **Gorin MA**, Rowe SP, Pienta KJ, Pomper MG, Wong J, Tran PT, Kang-Hsin Wang K. Online prostate-specific membrane antigen and positron emission tomography-guided radiation therapy for oligometastatic prostate cancer. *Adv Radiat Oncol* 2019; 5(2): 260-268.
114. Sahakyan K, Li X, Lodge MA, Werner RA, Bundschuh RA, Bundschuh L, Kulkarni HR, Schuchardt C, Baum RP, Pienta KJ, Pomper MG, Ross AE, **Gorin MA**, Rowe SP. Semiquantitative parameters in PSMA-targeted PET imaging with [¹⁸F]DCFPyL: inpatient and outpatient variability of normal organ uptake. *Mol Imaging Biol* 2020; 22(1): 181-189.
115. Werner RA, Bundschuh RA, Bundschuh L, Lapa C, Yin Y, Javadi MS, Buck AK, Higuchi T, Pienta KJ, Pomper MG, Lodge MA, **Gorin MA**, Rowe SP. Semiquantitative parameters in PSMA-targeted PET imaging with [¹⁸F]DCFPyL: impact of tumor burden on normal organ uptake. *Mol Imaging Biol* 2020; 22(1):190-197.
116. Nirschl TR, El Asmar M, Ludwig WW, Ganguly S, **Gorin MA**, Johnson MH, Pierorazio PM, Drake CG, Allaf ME, Zarif JC. Transcriptional profiling of tumor associated macrophages in human renal cell carcinoma reveals significant heterogeneity and opportunity for immunomodulation. *Am J Clin Exp Urol* 2020; 8(1):48-58.
117. Phillips R, Shi WY, Deek M, Radwan N, Lim SJ, Antonarakis ES, Rowe SP, Ross AE, **Gorin MA**, Deville C, Greco SC, Wang H, Denmeade SR, Paller CJ, Dipasquale S, DeWeese TL, Song DY, Wang H, Carducci MA, Pienta KJ, Pomper MG, Dicker AP, Eisenberger MA, Alizadeh AA, Diehn M, Tran PT. Outcomes of observation vs stereotactic ablative radiation for oligometastatic prostate cancer: the ORIOLE phase 2 randomized clinical trial. *JAMA Oncol* 2020; 6(5): 650-659.
118. **Gorin MA**, Meyer AR, Zimmerman M, Harb R, Joice GA, Schwen ZR, Allaf ME. Transperineal prostate biopsy with cognitive magnetic resonance imaging / biplanar ultrasound fusion: description of technique and early results. *World J Urol* 2020; 38(8): 1943-1949.
119. Tosoian JT, Mamawala M, Epstein JI, Landis P, Macura KJ, Simopoulos DN, Carter HB, **Gorin MA**. Active surveillance of grade group 1 prostate cancer: long-term outcomes from a large prospective cohort. *Eur Urol* 2020; 77(6): 675-682. Mamawala MK, Meyer A, Landis P, Macura KJ, Epstein JI, Partin AW, Carter HB, **Gorin MA**. Utility of multiparametric MRI in the risk stratification of men with grade group 1 prostate cancer on active surveillance. *BJU Int* 2020; 125(6): 861-866.
120. Liu C, Liu T, Zhang Z, Zhang N, Du P, Yang Y, Liu Y, Yu W, Li N, **Gorin MA**, Rowe SP, Zhu H, Yan K, Yang Z. ⁶⁸Ga-PSMA PET/CT combined with PET/ultrasound-guided prostate biopsy can diagnose clinically significant prostate cancer in men with previous negative biopsy results. *J Nucl Med* 2020; 61(9): 1314-1319.
121. Markowski MC, Sedhom R, Fu W, Gray JCR, Eisenberger MA, Pomper MG, Pienta KJ, **Gorin MA**, Rowe SP. PSA doubling time predict findings on ¹⁸F-DCFPyL PET/CT in patients with biochemically-recurrent prostate cancer. *J Urol* 2020; 204(3): 496-502.
122. Schwen ZR, Mamawala M, Tosoian JJ, Druskin SC, Ross AE, Sokoll LJ, Epstein JI, Carter HB, **Gorin MA**, Pavlovich CP. Prostate health index and multiparametric MRI to predict prostate cancer grade reclassification in active surveillance. *BJU Int* 2020; 126(3): 373-378.

123. Patel HD, Faisal FA, Trock BJ, Joice GA, Schwen ZR, Pierorazio PM, Johnson MH, Bivalacqua TJ, Han M, **Gorin MA**, Carter HB, Partin AW, Pavlovich CP, Allaf ME. Effect of pharmacologic prophylaxis on venous thromboembolism after radical prostatectomy: the PREVENTER randomized clinical trial. *Eur Urol* 2020; 78(3): 360-368.
124. Rowe SP, Meyer AR, Gorin MA, Chu LC, Fishman EK. Evaluation of the urinary bladder using three-dimensional CT cinematic rendering. *Diagn Interv Imaging* 2020; 101(12): 771-781.
125. Lodge MA, Lesniak W, **Gorin MA**, Pienta KJ, Rowe SP, Pomper MG. Measurement of PET quantitative bias in vivo. *J Nucl Med* 2020; 101(12): 771-781.
126. Khatri W, Chung HW, Werner RA, Leal JP, Pienta KJ, Lodge MA, **Gorin MA**, Pomper MG, Rowe SP. Effect of point-spread function reconstruction for indeterminate PSMA-RADS-3A lesions on PSMA-targeted PET imaging of men with prostate cancer. *Diagnostics (Basel)* 2021; 11(4): 665.
127. Meyer AR, Dharmaraja D, Harba R, Pavlovich CP, Allaf ME, **Gorin MA**. Perirectal hydrogel spacer placement prior to prostate radiation therapy using a probe-mounted needle guide. *Clin Transl Radiat Oncol* 2021; 29: 102-105.
128. Chalfin HJ, Glavaris SA, **Gorin MA**, Kates MR, Fong MH, Dong L, Matoso A, Bivalacqua TJ, Johnson MH, Pienta KJ, Hahn NM, McConkey DJ. Circulating tumor cell and circulating tumor DNA assays reveal complementary information for patients with metastatic urothelial cancer. *Eur Urol Oncol* 2021; 4(2): 310-314.
129. Meyer AR, Mamawala M, Winoker JS, Landis P, Epstein JI, Macura KJ, Allaf ME, Partin AW, Pavlovich CP, **Gorin MA**. Transperineal prostate biopsy improves the detection of clinically significant prostate cancer among men on active surveillance. *J Urol* 2021; 205(4): 1069-1074.
130. Su TZ, Patel HD, Huang MM, Meyer AR, Pavlovich CP, Pierorazio PM, Javadi MS, Allaf ME, Rowe SP, **Gorin MA**. Cost-effectiveness analysis of ^{99m}Tc-sestamibi single photon emission computed tomography/computed tomography to guide management of small renal masses. *Eur Urol Focus* 2021; 7(4): 827-834.
131. Markowski MC, Velho PI, Eisenberger MA, Pomper MG, Pienta KJ, **Gorin MA**, Antonarakis ES, Denmeade SR, Rowe SP. Detection of early progression with ¹⁸F-DCFPyL PET/CT in men with metastatic castration-resistant prostate cancer receiving bipolar androgen therapy. *J Nucl Med* 2021; 62(9): 1270-1273.
132. Patel HD, Schwen ZR, Campbell JD, **Gorin MA**, Partin AW, Burnett AL, Allaf ME. Effect of erythropoietin on erectile function after radical prostatectomy: the ERECT randomized clinical trial. *J Urol* 2021; 205(6): 1681-1688.
133. Pienta KJ, **Gorin MA**, Rowe SP, Carroll PR, Pouliot F, Probst S, Saperstein L, 7Mark A, Preston MA, Alva AS, Patnaik A, Durack JC, Stambler N, Lin T, Jensen J, Wong V, Siegel BA, Morris MJ, and OSPREY Study Group. A Phase 2/3 Prospective multicenter study of the diagnostic accuracy of prostate-specific membrane antigen PET/CT with ¹⁸F-DCFPyL in prostate cancer patients (OSPREY). *J Urol* 2021; 206(1): 52-61.
134. Morris MJ, Rowe SP, **Gorin MA**, Saperstein L, Pouliot F, Josephson D, Wong JYC, Pantel AR, Cho SY, Gage KL, Piert M, Iagaru A, Pollard JH, Wong V, Jensen J, Lin T, Stambler N, Carroll PR, Siegel BA and CONDOR Study Group. Diagnostic performance of ¹⁸F-DCFPyL PET/CT in men with biochemically recurrent prostate cancer: results from the CONDOR phase 3, multicenter study. *Clin Cancer Res* 2021; 27(13): 3674-3682.
135. De Silva RA, **Gorin MA**, Mease RC, Minn I, Lisok A, Plyku D, Nimmagadda S, Allaf ME, Yang X, Sgouros G, Rowe SP, Pomper MG. Process validation, cGMP production, dosimetry, and toxicity studies of the CAIX imaging agent [¹¹¹In]XYIMSR-01 for phase I regulatory approval. *J Labelled Comp Radiopharm* 2021; 64(6): 243-250.
136. Zukotynski KA, Emmenegger U, Hotte S, Kapoor A, Fu W, Blackford AL, Valliant J, Benard F, Kim CK, Markowski MC, Eisenberger MA, Antonarakis ES, Pienta KJ, **Gorin MA**, Lubanovic M, Kim J, Pomper MG, Cho SY, Rowe SP. Prospective, single-arm trial evaluating changes in uptake patterns on prostate-specific membrane antigen (PSMA)-targeted ¹⁸F-DCFPyL PET/CT in patients with castration-resistant prostate cancer starting abiraterone or enzalutamide. *J Nucl Med* 2021; 62(10): 1430-1437.

137. Okhunov Z, **Gorin MA**, Jefferson FA, Afyouni AS, Allaf ME, Pierorazio PM, Patel RM, Huynh LM, Tapiero S, Osann K, Kavoussi LR, Clayman RV, Landman J. Can preoperative renal mass biopsy change clinical practice and reduce surgical intervention for small renal masses? *Urol Oncol* 2021; 39(10): 735.e17-735.e23.
138. **Gorin MA**, Patel HD, Rowe SP, Hahn NM, Hammers HJ, Pons A, Trock BJ, Pierorazio PM, Nirschl TR, Salles DC, Stein JE, Lotan TL, Taube JM, Drake CG, Allaf ME. Neoadjuvant nivolumab in patients with high-risk nonmetastatic renal cell carcinoma. *Eur Urol Oncol*; in press.
139. Dong L, Su Y, Zhu Y, Markowski MC, Xin M, **Gorin MA**, Dong B, Pan J, Pomper MG, Liu J, Pienta KJ, Xue W, Rowe SP. The European Association of Urology biochemical recurrence risk groups predict findings on PSMA PET in patients with biochemically recurrent prostate cancer after radical prostatectomy. *J Nucl Med*; in press.
140. Tang M, Wang L, **Gorin MA**, Taylor JMG. Step-adjusted tree-based reinforcement learning for evaluating nested dynamic treatment regimes using test-and-treat observational data. *Stat Med*; in press.
141. Setia S, Smith J, Cendo D, **Gorin MA**, Allaway M, Vourganti S. Outcomes of freehand transperineal prostate biopsy with omission of antibiotic prophylaxis. *BJU Int*; in press.
142. Setia S, Jackson J, Cendo D, **Gorin MA**, Allaway M, Vourganti S. Assessing the diagnostic performance of systematic freehand precisionpoint transperineal prostate biopsy: comparison of observed outcomes to PBCG nomogram predictions. *Urol Oncol*; in press.
143. Mena E, Rowe SP, Shih JH, Lindenberg L, Turkbey B, Fourquet A, Lin FI, Adler S, Eclarinal P, McKinney YL, Citrin DE, Dahut W, Wood BJ, Chang R, Levy E, Merino M, **Gorin MA**, Pomper MG, Pinto PA, Eary JF, Choyke PL, Pienta KJ. Predictors of ¹⁸F-DCFPyL-PET/CT positivity in patients with biochemical recurrence of prostate cancer after local therapy. *J Nucl Med*; in press.
144. Sood A, Jeong W, Palma-Zamora I, Abdollah F, Butaney M, Corsi N, Wurst H, Arora S, Kachroo N, Hassan O, Gupta N, **Gorin MA**, Menon M. Description of surgical technique and oncologic and functional outcomes of the precision prostatectomy procedure (IDEAL Stage 1-2b study). *Eur Urol*; in press.
145. Werner RA, Habacha B, Lütje S, Bundschuh L, Higuchi T, Hartramp P, Serfling SE, Derlin, Lapa C, Buck AK, Markus E, Pienta KJ, Eisenberger MA, Markowski MC, Shinehouse L, AbdAllah R, Salavati A, Lodge MA, Pomper MG, **Gorin MA**, Bundschuh RA, Rowe SP. High SUVs have more robust repeatability in patients with metastatic prostate cancer: results from a prospective test-retest cohort imaged with ¹⁸F-DCFPyL. *Mol Imaging*; in press.

Review Articles

1. **Gorin MA**, Pan Q. Protein kinase C ϵ : an oncogene and emerging tumor biomarker. *Mol Cancer* 2009; 8(1): 9.
2. Shatry A, Chirinos J, **Gorin MA**, Jones M, Levy RB. Targeting Treg cells *in situ*: emerging expansion strategies for (CD4⁺CD25⁺) regulatory T cells. *Biol Blood Marrow Transplant* 2009;15(10): 1239-43.
3. Pan Q, **Gorin MA**, Teknos TN. Pharmacotherapy of head and neck squamous cell carcinoma. *Expert Opin Pharmacother* 2009;10(14): 2291-302.
4. **Gorin MA**, Ayyathurai R, Soloway MS. Transurethral management of urothelial carcinoma of the bladder. *AUA Update Series* 2011; 30(23): 209-20.
5. **Gorin MA**, Ayyathurai R Soloway MS. Diagnosis and treatment of bladder cancer: how can we improve? *Postgrad Med* 2012; 124(3): 28-36.
6. **Gorin MA**, Allaf ME. Radiofrequency ablation of small renal mass—more work required. *Nat Rev Urol* 2012; 9(6): 297-8.
7. **Gorin MA**, Gonzalez J, Garcia-Roig M, Ciancio G. Transplantation techniques for the resection of renal cell carcinoma with tumor thrombus: a technical description and review. *Urol Oncol* 2013; 31(8): 1780-7.
8. Ball MW, **Gorin MA**, Allaf ME. Reducing morbidity of pelvic and retroperitoneal lymphadenectomy. *Curr Urol Rep* 2013; 14(5): 488-95.
9. Gonzalez J, **Gorin MA**, Garcia-Roig M, Ciancio G. Inferior vena cava resection and reconstruction: technical considerations in the surgical management of renal cell carcinoma with tumor thrombus. *Urol Oncol* 2014; 32(1): 34.e19-26.
10. Marconi L, **Gorin MA**, Allaf ME. Post partial nephrectomy surveillance imaging: an evidence-based approach. *Curr Urol Rep* 2015; 16(4): 23.

11. **Gorin MA**, Soloway MS. Active surveillance with delayed intervention for recurrent low-risk bladder cancer. *Urology Practice* 2015; 2(5): 256-59.
12. **Gorin MA**, Rowe SP, Allaf ME. Nuclear imaging of renal tumours: a step towards improved risk stratification. *Nat Rev Urol* 2015; 12(8): 445-50.
13. **Gorin MA**, Rowe SP, Allaf ME. Envisioning a novel approach for the risk stratification of small renal tumors. *Kidney Cancer Journal* 2015; 13(3): 54-59.
14. Nickel JC, **Gorin MA**, Partin AW, Assimos D, Brawer M, Nicolai H, Chancellor MB, Goggins Á, Loeb S, Shapiro E. Best of the 2015 AUA annual meeting: highlights from the 2015 American Urological Association annual meeting, May 15-19, 2015, New Orleans, LA. *Rev Urol* 2015; 17(3): 179-89.
15. Campbell SP, Song DY, Pierorazio PM, Allaf ME, **Gorin MA**. Stereotactic ablative radiotherapy for the treatment of clinically localized renal cell carcinoma. *J Oncol* 2015; 2015: 1-6.
16. **Gorin MA**, Rowe SP, Allaf ME. Oncocytic neoplasm on renal mass biopsy: a clinical conundrum. *Oncology (Williston Park)* 2016; 30(5): 426-8.
17. Rowe SP, **Gorin MA**, Allaf ME, Pienta KJ, Tran PT, Pomper MG, Ross AE, Cho SY. PET imaging of prostate-specific membrane antigen in prostate cancer: current state of the art and future challenges. *Prostate Cancer Prostatic Dis* 2016; 19(3): 223-30. Rowe SP, Drzezga A, Neumaier B, Dietlein M,
18. **Gorin MA**, Zalutsky MR, Pomper MG. Prostate-specific membrane antigen-targeted radiohalogenated PET and therapeutic agents for prostate cancer. *J Nucl Med* 2016; 57(Suppl 3): 90S-6S.
19. Nickel JC, **Gorin MA**, Alan W P, Loeb S, Ellen S, Chancellor MB, Assimos DG, Brawer MK, Brucker BM. Best of the 2016 AUA annual meeting: highlights from the 2016 American Urological Association annual meeting, May 6-10, 2016, San Diego, CA. *Rev Urol* 2016; 18: 159-73.
20. **Gorin MA**, Rowe SP, Allaf ME. Noninvasive determination of renal tumor histology utilizing molecular imaging. *Urol Oncol* 2016; 34: 525-8.
21. van der Toom EE, Verdone JE, **Gorin MA**, Pienta KJ. Technical challenges in the isolation and analysis of circulating tumor cells. *Oncotarget* 2016; 7: 62754-66.
22. Tosoian JJ, **Gorin MA**, Ross AE, Pienta KJ, Tran PT, Schaeffer EM. Oligometastatic prostate cancer: definitions, clinical outcomes, and treatment considerations. *Nat Rev Urol* 2017; 14: 15-25.
23. **Gorin MA**, Rowe SP, Denmeade SR. Clinical applications of molecular imaging in the management of prostate cancer. *PET Clin* 2017; 12: 185-192.
24. Rowe SP, **Gorin MA**, Salas Fragomeni RA, Drzezga A, Pomper MG. Clinical experience with ¹⁸F-labeled small molecule inhibitors of prostate-specific membrane antigen. *PET Clin* 2017; 12: 235-241.
25. Rowe SP, **Gorin MA**, Pomper MG. Imaging of Prostate-Specific Membrane Antigen Using [¹⁸F]DCFPyL. *PET Clin*. 2017; 12: 289-296.
26. **Gorin MA**, Verdone JE, van der Toom E, Bivalacqua TJ, Allaf ME, Pienta KJ. Circulating tumour cells as biomarkers of prostate, bladder, and kidney cancer. *Nat Rev Urol* 2017; 14: 90-97.
27. Sheikhabaehi S, Afshar-Oromieh A, Eiber M, Solnes LB, Javadi MS, Ross AE, Pienta KJ, Allaf ME, Haberkorn U, Pomper MG, **Gorin MA**, Rowe SP. Pearls and pitfalls in clinical interpretation of prostate-specific membrane antigen (PSMA)-targeted PET imaging. *Eur J Nucl Med Mol Imaging* 2017; 44(12): 2117-2136.
28. Rowe SP, Javadi MS, Allaf ME, **Gorin MA**. Characterization of indeterminate renal masses with molecular imaging: how do we turn potential into reality? *EJNMMI Res* 2017; 7(1): 34.
29. Joice GA, Rowe SP, Pienta KJ, **Gorin MA**. Oligometastatic prostate cancer: shaping the definition with molecular imaging and an improved understanding of tumor biology. *Curr Opin Urol* 2017; 27(6): 533-541.
30. Ludwig WW, **Gorin MA**, Pierorazio PM, Allaf ME. Frontiers in robot-assisted retroperitoneal oncological surgery. *Nat Rev Urol* 2017; 14(12): 731-741.
31. **Gorin MA**, Rowe SP. PSMA: a potential therapeutic target in RCC. *Nat Rev Urol*; 2017; 14(11): 646-647.
32. Li R, Ravizzini GC, **Gorin MA**, Maurer T, Eiber M, Cooperberg MR, Alemozzaffar M, Tollefson MK, Delacroix SE, Chapin BF. The use of PET/CT in prostate cancer. *Prostate Cancer Prostatic Dis* 2018; 21(1): 4-21.
33. Campbell SP, Tzortzakakis A, Javadi MS, Karlsson M, Solnes LB, Axelsson R, Allaf ME, **Gorin MA**, Rowe SP. ^{99m}Tc-Sestamibi SPECT/CT for the characterization of renal masses: a pictorial guide. *Br J Radiol* 2018; 91: 1084.

34. Golan R, Bernstein A, Sedrakyan A, Daskivich TJ, Du DT, Ehdaie B, Fisher B, **Gorin MA**, Grunberger I, Hunt B, Jiang HH, Kim HL, Marinac-Dabic D, Marks LS, McClure TD, Montgomery JS, Parekh DJ, Punnen S, Scionti S, Viviano CJ, Wei JT, Wenske S, Wysock JS, Rewcastle J, Carol M, Oczachowski M, Hu JC. Development of a nationally-representative coordinated registry network for prostate ablation technologies. *J Urol* 2018; 199(6): 1488-93.
35. Meyer AR, Allaf ME, Rowe SP, **Gorin MA**. The role of molecular imaging in the characterization of renal masses. *Curr Opin Urol* 2018; 28(2): 159-65.
36. Rowe SP, Pomper MG, **Gorin MA**. Molecular imaging of prostate cancer: choosing the right agent. *J Nucl Med* 2018; 59(5): 787-8.
37. Salas Fragomeni RA, Amir T, Sheikhabaei S, Harvey SC, Javadi MS, Solnes L, Kiess A, Allaf ME, Pomper M, **Gorin MA**, Rowe SP. Imaging of non-prostate cancers using PSMA-targeted radiotracers: rationale, current state of the field, and a call to arms. *J Nucl Med* 2018; 59(6): 871-7.
38. Werner RA, Andree C, Javadi MS, Lapa C, Buck AK, Higuchi T, Pomper MG, **Gorin MA**, Rowe SP, Pienta KJ. A voice from the past: re-discovering the Virchow node with PSMA-targeted ¹⁸F-DCFPyL PET imaging. *Urology* 2018; 117:18-21.
39. Miyahira AK, Pienta KJ, Morris MJ, Bander NH, Baum RP, Fendler WP, Goeckeler W, **Gorin MA**, Hennekes H, Pomper MG, Sartor O, Tagawa ST, Williams S, Soule HR. Meeting report from the Prostate Cancer Foundation PSMA-directed radionuclide scientific working group. *Prostate* 2018; 78(11): 775-89.
40. Joice GA, Rowe SP, **Gorin MA**, Pierorazio PM. Molecular imaging for evaluation of viable testicular cancer nodal metastases. *Curr Urol Rep* 2018; 19(12): 110.
41. Azadi J, Nguyen ML, Leroy A, Macura KJ, **Gorin MA**, Rowe SP. The emerging role of imaging in prostate cancer secondary screening: multiparametric magnetic resonance imaging and the incipient incorporation of molecular imaging. *Br J Radiol* 2018; 91(1090): 20170960.
42. Werner RA, Bundschuh RA, Bundschuh L, Javadi MS, Higuchi T, Weich A, Sheikhabaei S, Pienta KJ, Buck AK, Pomper MG, **Gorin MA**, Lapa C, Rowe SP. Molecular imaging reporting and data systems (MIRADS): a generalizable framework for targeted radiotracers with theranostic implications. *Ann Nucl Med* 2018; 32(8): 512-522.
43. Meyer AR, Joice GA, Allaf ME, Rowe SP, **Gorin MA**. Integration of PSMA-targeted PET imaging into the armamentarium for detecting clinically significant prostate cancer. *Curr Opin Urol* 2018; 28(6): 493-498.
44. Rowe SP, Pienta KJ, Pomper MG, **Gorin MA**. Proposal of a structured reporting system for prostate-specific membrane antigen (PSMA)-targeted PET imaging: PSMA-RADS version 1.0. *J Nucl Med* 2018; 59(3): 479-485.
45. Rowe SP, Pienta KJ, Pomper MG, **Gorin MA**. PSMA-RADS version 1.0: a step towards standardizing the interpretation and reporting of PSMA-targeted PET imaging studies. *Eur Urol* 2018; 73(4): 485-487.
46. Rowe SP, **Gorin MA**, Pomper MG. Imaging of prostate-specific membrane antigen with small-molecule PET radiotracers: from the bench to advanced clinical applications. *Annu Rev Med* 2019; 70: 461-477.
47. Gross MD, Sedrakyan A, Bianco FJ, Carroll PR, Daskivich TJ, Eggener SE, Ehdaie B, Fisher B, **Gorin MA**, Hunt B, Jiang H, Klein EA, Marinac-Dabic D, Montgomery JS, Polascik TJ, Priester AM, Rastinehad AR, Viviano CJ, Wysock JS, Hu JC. Study of prostate ablation related energy devices (SPARED) collaboration: patient selection for partial gland ablation in men with localized prostate cancer. *J Urol* 2019; 202(5): 952-958.
48. Werner RA, Bundschuh R, Bundschuh L, Fanti S, Javadi MS, Higuchi T, Weich A, Pienta KJ, Buck AK, Pomper MG, **Gorin MA**, Herrmann K, Lapa C, Rowe SP. Novel Structured Reporting Systems for Theranostic Radiotracers. *J Nucl Med* 2019; 60(5): 577-584.
49. Sheikhabaei S, Werner RA, Solnes LB, Pienta KJ, Pomper MG, **Gorin MA**, Rowe SP. Prostate-specific membrane antigen (PSMA)-targeted PET imaging of prostate cancer: an update on important pitfalls. *Semin Nucl Med* 2019; 49(4): 255-270.
50. Meyer AR, **Gorin MA**. First point-of-care PSA test for prostate cancer detection. *Nat Rev Urol* 2019; 16(6): 331-332.
51. Zimmerman ME, Meyer AR, Rowe SP, **Gorin MA**. Imaging of prostate cancer with positron emission tomography. *Clin Adv Hematol Oncol* 2019; 17(8): 455-463.
52. Patel HD, Semerjian A, Gupta M, Pavlovich CP, Johnson MH, **Gorin MA**, Allaf ME, Pierorazio PM. Surgical removal of renal tumors with low metastatic potential based on clinical radiographic size: A systematic review of the literature. *Urol Oncol* 2019; 37(8): 519-524.

53. Werner RA, Derlin T, Lapa C, Sheikbahaei S, Higuchi T, Giesel FL, Behr S, Drzezga A, Kimura H, Buck AK, Bengel FM, Pomper MG, **Gorin MG**, Rowe SP. ¹⁸F-Labeled, PSMA-targeted radiotracers: leveraging the advantages of radiofluorination for prostate cancer molecular imaging *Theranostics* 2020; 10(1):1-16.
54. Connor MJ, **Gorin MA**, Ahmed HU, Nigam R. Focal therapy for localized prostate cancer in the era of routine multi-parametric MRI. *Prostate Cancer Prostatic Dis* 2020; 23(2): 232-243.
55. Bhanji, Y, Allaway MJ, **Gorin MA**. Recent advances and current role of transperineal prostate biopsy. *Urol Clin North Am* 2021; 48(1): 25-33.
56. Rowe SP, Johnson GB, Pomper MG, **Gorin MA**, Behr SC. Recent updates and developments in PET imaging of prostate cancer. *Abdom Radiol (NY)* 2020; 45(12): 4063-4072.
57. Basourakos SP, Tzeng M, Lewicki PJ, Patel K, Awamlh BAHA, Venkat S, Shoag JE, **Gorin MA**, Barbieri CE, Hu JC. Tissue-based biomarkers for the risk stratification of men with clinically localized prostate cancer. *Front Oncol* 2021; 11: 676716.
58. Mena E, Black PC, Rais-Bahrami S, **Gorin M**, Allaf M, Choyke P. Novel PET imaging methods for prostate cancer. *World J Urol* 2021; 39(3): 687-699.
59. Basourakos SP, Allaway MJ, Ross AE, Schaeffer EM, Hu JC, **Gorin MA**. Anaesthetic techniques for performing transperineal prostate biopsy. *Nat Rev Urol* 2021; 18(6): 315-317.
60. Sadaghiani MS, Sheikbahaei S, Werner RA, Pienta KJ, Pomper MG, Solnes LB, **Gorin MA**, Wang NY, Rowe SP. A Systematic review and meta-analysis of the effectiveness and toxicities of lutetium-177-labeled prostate-specific membrane antigen-targeted radioligand therapy in metastatic castration-resistant prostate cancer. *Eur Urol* 2021; 80(1): 82-94.
61. Knaub RJ, Allaf ME, **Gorin MA**. Freehand transperineal prostate biopsy with three-dimensional ultrasound organ-based tracking. *J Endourol* 2021; 35(S2): S7-S16.
62. Rowe SP, Buck A, Bundschuh RA, Lapa C, Serfling SE, Derlin T, Higuchi T, **Gorin MA**, Pomper MG, Werner RA. [¹⁸F]DCFPyL PET/CT for imaging of prostate cancer. *Nuklearmedizin*; in press.
63. Roussel E, Capitanio U, Kutikov A, Oosterwijk E, Pedrosa I, Rowe SP, **Gorin MA**. Novel imaging methods for renal mass characterization: a collaborative review. *Eur Urol*; in press.
64. Basourakos SP, Alshak M, Lewicki PJ, Cheng E, Tzeng M, DeRosa AP, Allaway MJ, Ross AE, Schaeffer EM, Patel HD, Hu JC, **Gorin MA**. The role of prophylactic antibiotics in transperineal prostate biopsy: a systematic review and metanalysis. *Eur Urol Open Sci*; in press.

Case Reports

1. Ekwenna O, **Gorin MA**, Castellan M, Casillas V, Ciancio G. Inverted nutcracker syndrome: a case of persistent hematuria and pain in the presence of a left-sided inferior vena cava. *TheScientificWorldJOURNAL: TSW Urology* 2011; 5(11): 1031-5.
2. **Gorin MA**, Antebi E, Manoharan M, Bird VG. Endoscopic retrieval of a retained self-expanding metal stent placed for a ureteroileal anastomotic stricture. *J Endourol* 2011; 25(6): 911-2.
3. Lveillee RJ, Castle SM, **Gorin MA**, Salas N, Gorbatiy V. Initial experience with LESS simple nephrectomy using the TransEnterix SPIDER surgical system: assessing feasibility and safety. *J Endourol* 2011; 25(6): 923-5.
4. Gahan J, Shirodkar SP, **Gorin MA**, Salerno TA, Ciancio G. Surgical resection of a virilizing adrenal mass with extensive tumor thrombus. *Can J Urol* 2011; 18(3): 5735-8.
5. **Gorina MA**, Garcia-Roig M, Burke GW, Ciancio G. Emergent renal revascularization of a simultaneous kidney-transplant recipient. *Transplantation* 2012; 93(4): e16-7.
6. **Gorin MA**, Ekwenna O, Soloway MS, Ciancio G. Dramatic reduction in tumor burden with neoadjuvant sunitinib prior to bilateral nephron-sparing surgery. *Urology* 2012; 79(2): e11.
7. **Gorin MA**, Gorbatiy V, Glenn C, Shirodkar SP, Castle SM, Jorda M, Leveillee RJ. Salvage robot-assisted partial nephrectomy for the management of renal cell carcinoma following failed primary treatment with stereotactic radiotherapy. *JSLs* 2012; 16(1): 159-62.
8. Moore C, Shirodkar SP, Avallone M, Castle SM, **Gorin MA**, Gorbatiy V, Leveillee RJ. Intravesical methylene blue facilitates precise identification of the diverticular neck during robot-assisted laparoscopic bladder diverticulectomy. *J Laparoendosc Adv Surg Tech A* 2012; 22(5): 492-5.
9. **Gorin MA**, Mullins JK, Allaf ME. Metastatic non-seminomatous germ cell tumor with vena cava and vertebral involvement. *Int J Urol* 2013; 20(4): 459-60.

10. Joshi S, **Gorin MA**, Ciancio G. Release of the inferior vena cava ligament during caval thrombectomy causing tumor thrombus embolization. *Urol Int* 2013; 90(4): 490-2.
11. Rowe SP, Deville C, Paller C, Cho SY, Fishman EK, Pomper MG, Ross AE, **Gorin MA**. Uptake of ¹⁸F-DCFPyL in Paget's disease of bone, an important potential pitfall in clinical interpretation of PSMA PET studies. *Tomography* 2015; 1(2): 81-4.
12. Rowe SP, Mana-ay M, Javadi MS, Szabo Z, Leal JP, Pomper MG, Pienta KJ, Ross AE, **Gorin MA**. PSMA-based detection of prostate cancer bone lesions with ¹⁸F-DCFPyL PET/CT: a sensitive alternative to ^{99m}Tc-MDP bone scan and Na¹⁸F PET/CT? *Clin Genitourin Cancer* 2016; 14(1): e115-8.
13. Rowe SP, **Gorin MA**, Hammers HJ, Allaf ME, Pomper MG, Javadi MS. Detection of ¹⁸F-FDG PET/CT occult lesions with ¹⁸F-DCFPyL PET/CT in a patient with metastatic renal cell carcinoma. *Clin Nucl Med* 2016; 41(1): 83-5.
14. Tosoian TJ, Reyes DK, **Gorin MA**, Hortopan S, Partin AW, Pienta KJ, Ross AE, Schaeffer EM. A novel approach for performing bone marrow aspiration at the time of radical prostatectomy. *Urol Case Rep* 2016; 6: 45-6.
15. Campbell SP, Rowe SP, **Gorin MA**, Allaf ME. Renal pseudoaneurysm mimicking local cancer recurrence after partial nephrectomy. *Urol Case Rep* 2016; 11: 1-3.
16. Tosoian JJ, **Gorin MA**, Rowe SP, Andreas D, Szabo Z, Pienta KJ, Pomper MG, Lotan TL, Ross AE. Correlation of PSMA-targeted ¹⁸F-DCFPyL PET/CT findings with immunohistochemical and genomic data in a patient with metastatic neuroendocrine prostate cancer. *Clin Genitourin Cancer*. 2017; 15: e65-e68.
17. Rowe SP, **Gorin MA**, Javadi MS, Allaf ME. Evaluation of a large renal mass using ^{99m}Tc-MIBI SPECT/CT in a patient with chronic kidney disease. *Clin Nucl Med* 2017; 42: e166-e167.
18. Rowe SP, **Gorin MA**, Chu LC, Pienta KJ, Pomper MG, Ross AE, Macura KJ. An unusual case of penile prostate cancer uncovered by multiparametric MRI and PSMA-targeted ¹⁸F-DCFPyL PET/CT. *Clin Nucl Med* 2017; 42(10): e441-e443.
19. Zarif JC, Chalfin HJ, Pierorazio PM, **Gorin MA**. Characterization of the macrophage infiltrate in a case of xanthogranulomatous pyelonephritis. *J Clin Urol* 2018; 11(3): 226-228.
20. **Gorin MA**, Pienta KJ, Pomper MG, Rowe SP. Prostate cancer local recurrence detected with both ¹⁸F-fluciclovine and PSMA-targeted ¹⁸F-DCFPyL PET/CT. *Urology* 2017; 107: e9-e10.
21. Phillips RM, **Gorin MA**, Rowe SP, Pomper MG, Pienta KJ, Ross AE, Tran PT. Complete biochemical response after stereotactic ablative radiotherapy of an isolated prostate cancer pelvic soft tissue recurrence detected by ¹⁸F-DCFPyL PET/CT. *Urol Case Rep* 2017; 16: 86-8.
22. Shenderov E, **Gorin MA**, Kim S, Johnson PT, Allaf ME, Partin AW, Pomper MG, Antonarakis ES, Pienta KJ, Rowe SP. Diagnosing small bowel carcinoid tumor in a patient with oligometastatic prostate cancer imaged with PSMA-targeted [¹⁸F]DCFPyL PET/CT: value of the PSMA-RADS-3D designation. *Urol Case Rep*. 2017; 17: 22-25.
23. Almassi N, **Gorin MA**, Purysko A, Rowe SP, Kaouk J, Allaf ME, Campbell SC, Rhee A. Use of ^{99m}Tc-sestamibi SPECT/CT in the diagnosis of hybrid oncocytic/chromophobe tumor in a pediatric patient. *Urology* 2018; 113: 206-8.
24. Srivastava A, Meyer AR, Pierorazio PM, Rowe SP, Allaf ME, **Gorin MA**. Spontaneous regression of a low-grade renal cell carcinoma with oncocytic features after renal mass biopsy. *Clin Genitourin Cancer* 2018; 16(6): e1083-e1085.
25. Salas Fragomeni RA, Pienta KJ, Pomper MG, **Gorin MA**, Rowe SP. Uptake of prostate-specific membrane antigen-targeted ¹⁸F-DCFPyL in cerebral radionecrosis: implications for diagnostic imaging of high-grade gliomas. *Clin Nucl Med* 2018; 43(11): e419-e421.
26. Reyes DK, Demehri S, Werner RA, Pomper MG, **Gorin MA**, Rowe SP, Pienta KJ. PSMA-targeted [¹⁸F]DCFPyL PET/CT-avid lesions in a patient with prostate cancer: Clinical decision-making informed by the PSMA-RADS interpretive framework. *Urol Case Rep* 2019; 23: 72-74.
27. Sahakyan K, Spevak MR, Ziessman HA, **Gorin MA**, Rowe SP. The scintigraphic drooping lily sign. *Clin Nucl Med* 2018; 43(5) 352-3.
28. Gomez E, Tran PT, Pienta KJ, Pomper MG, **Gorin MA**, Rowe SP. Hereditary spherocytosis presenting as diffuse bone marrow activation and splenomegaly on PSMA-targeted ¹⁸F-DCFPyL PET/CT. *Clin Nucl Med* 2019; 44: e313-4.
29. Meyer AR, Leroy A, Allaf ME, Rowe SP, **Gorin MA**. Incidentally detected ¹⁸F-FDG-avid prostate cancer diagnosed using a novel fusion biopsy platform. *J Endourol Case Rep* 2019 5(2): 68-70.

30. Torga G, Yin Y, Pomper MG, Pienta KJ, **Gorin MA**, Rowe SP. Uptake of prostate-specific membrane antigen-targeted ¹⁸F-DCFPyL in avascular necrosis of the femoral head. *World J Nucl Med* 2019; 18(4):416-419.
31. Yin Y, Paller CJ, Pomper MG, Pienta KJ, **Gorin MA**, Rowe SP. Vas deferens infiltration by prostate cancer on prostate-specific membrane antigen-targeted ¹⁸F-DCFPyL positron emission tomography/computed tomography: A unique visual pattern. *World J Nucl Med* 2019; 18(4): 424-427.

Editorials

1. Soloway MS, **Gorin MA**, Katkooori D. Definitive therapy for cancer: is our message clear? *Eur Urol* 2010; 58(2): 256-57.
2. **Gorin MA**, Kava BR, Leveillee RJ. Video demonstrations as an intraoperative teaching aid for surgical assistants. *Eur Urol* 2011; 59(2): 306-7.
3. Jenkins LC, **Gorin MA**, Ciancio G. Words of Wisdom. Re: Radical nephrectomy and inferior vena cava thrombectomy: outcomes in a lower volume practice. *Eur Urol* 2011; 60(6): 1305-6.
4. Soloway MS, Garcia-Roig M, **Gorin MA**, Ayyathurai R. How can we improve outcomes for upper tract urothelial carcinoma? *Eur Urol* 2012; 61(2): 254-6
5. **Gorin MA**, Garcia-Roig M, Ciancio G. Words of Wisdom. Re: Posterior lumbar vein off the retrohepatic inferior vena cava: a novel anatomical variant with surgical implications. *Eur Urol* 2012; 61(4): 849.
6. Soloway MS, **Gorin MA**. Words of Wisdom. Re: Adjuvant radiotherapy following radical prostatectomy for prostate cancer. *Eur Urol* 2012; 61(5): 1065
7. González J, Ciancio G, **Gorin MA**. Long-term survival after radical surgery for renal cell carcinoma with tumour thrombus. *BJU Int* 2013; 111(3): E8-9
8. Ludwig W, **Gorin MA**, Allaf ME. Reducing the cost of robotic partial nephrectomy through innovative instrument use. *Eur Urol* 2015; 67(3): 594-5.
9. **Gorin MA**, Pomper MG, Rowe SP. PSMA-targeted imaging of prostate cancer: the best is yet to come. *BJU Int* 2016; 117(5): 715-6.
10. **Gorin MA**, Pomper MG, Pienta KJ, Rowe SP. Defining the clinical utility of PSMA-targeted PET imaging of prostate cancer. *BJU Int* 2017; 120(2): 160-161.
11. Chalfin HJ, Pienta KJ, **Gorin MA**. Selection-free method reveals phenotypic diversity among prostate cancer circulating tumour cells. *BJU Int* 2017; 120(5B): E4.
12. **Gorin MA**, Walsh PC. Magnetic resonance imaging prior to first prostate biopsy-are we there yet? *Eur Urol* 2018; 74(4): 409-410.
13. Meyer AR, Rowe SP, **Gorin MA**. Preoperative PSMA-targeted PET imaging: more than just a tool for prostate cancer staging? *BJU Int* 2019; 124(1): 2-3.
14. Batra JS, Pienta KJ, Pomper MG, **Gorin MA**, Rowe SP. Can the interplay between androgen signaling and PSMA expression be leveraged for theranostic applications? *Transl Androl Urol* 2019; 8(Suppl 3): S263-S264.
15. Grummet J, **Gorin MA**, Popert R, Hadaschik B, Radtke JP, Wagenlehner F, Moore CM, Emberton M, George AK, Davis JW, Szabo R, Buckley R, Loblaw A, Allaway M, Kastner C, Royce P, Frydenberg M, Murphy DG, Woo HH. TREXIT 2020: why the time to abandon transrectal prostate biopsy starts now. *Prostate Cancer Prostatic Dis* 2020; 23(1): 62-65.
16. Rowe SP, **Gorin MA**, Pomper MG. Prostate-specific membrane antigen (PSMA) imaging: the past is prologue and the future is scintillating. *Transl Androl Urol* 2020; 9(2): 840-842.
17. Grummet JP, Mottet N, **Gorin MA**. TREXIT is now: should we abandon the transrectal route for prostate biopsy? Yes. *Eur Urol Open Sci* 2021; 31: 14-16.

Letters / Correspondence

1. **Gorin MA**, Garcia-Roig M, Shirodkar SP, Gonzalez J, Ciancio G. Reply to Comment Re: Modified surgical technique for the management of renal cell carcinoma with level I or II tumor thrombus. *Urology* 2012; 79(2): 481-2.
2. **Gorin MA**, Allaf ME. Editorial Comment Re: A single overnight stay is possible for the majority patients undergoing robotic partial nephrectomy. *Urology* 2013; 81(2): 307.
3. **Gorin MA**, Sagalowsky AI, Soloway MS. Editorial Comment Re: Upper urinary tract recurrence following radical cystectomy for bladder cancer: a meta-analysis on 13,185 patients. *J Urol* 2013; 190(1): 360-1.

4. Allaf ME, **Gorin MA**. Editorial Comment Re: Robotic partial nephrectomy for renal cell carcinomas with venous tumor thrombus. *Urology* 2013; 81(6): 1367.
5. Bivalacqua TJ, **Gorin MA**, Walsh PC. Reply to Editorial Comment Re: Anatomical extent of pelvic lymph node dissection: impact on long-term cancer-specific outcomes in men with positive lymph nodes at time of radical prostatectomy. *Urology* 2013; 82(3): 65.
6. Chalfin H, **Gorin MA**, Allaf ME. Editorial comment on: Mayo Adhesive Probability (MAP) score is associated with localized renal cell carcinoma progression-free survival. *Urology* 2016; 89: 61.
7. Meyer A, **Gorin MA**. Editorial comment Re: Percent of Tracer Clearance at 40 min in MAG3 renal scans is more sensitive than T1/2 for symptomatic UPJ obstruction. *Urology* 2017; 103: 249-250.
8. Campbell SC, McKenney JK, Almassi N, **Gorin MA**, Rowe SP, Purysko AS, Kaouk J, Allaf ME, Rhee A. Re: Use of ^{99m}Tc-sestamibi single-photon emission computed tomography / x-ray computed tomography in the diagnosis of hybrid oncocytic/chromophobe tumor in a pediatric patient. *Urology* 2018; 116: 234-5.
9. Werner RA, Pienta KJ, Pomper MG, **Gorin MA**, Rowe SP, Lodge MA, Bundschuh RA. Letter to the Editor re: Semiquantitative parameters in PSMA-targeted PET imaging with ¹⁸F-DCFPyL: impact of tumor burden on normal Organ Uptake. *Mol Imaging Biol* 2020; 22(1): 19-21.
10. Bhanji Y, **Gorin MA**. Editorial comment on: Transperineal versus transrectal targeted biopsy with use of electromagnetically-tracked MR/US fusion guidance platform for the detection of clinically significant prostate cancer. *Urology* 2020; 146: 285-286.
11. Winoker JS, **Gorin MA**. Editorial comment on: Comment on transperineal free-hand mpMRI fusion-targeted biopsies under local anesthesia: technique and feasibility from a single-centre prospective study. *Urology* 2020; 140: 130.
12. Pienta KJ, **Gorin MA**, Rowe SP, Carroll PR, Pouliot F, Probst S, Saperstein L, Preston MA, Alva AS, Patnaik A, Durack JC, Stambler N, Lin T, Jensen J, Wong V, Siegel BA, Morris MJ; OSPREY Study Group. Reply by authors to comment re: A phase 2/3 prospective multicenter study of the diagnostic accuracy of prostate specific membrane antigen PET/CT with ¹⁸F-DCFPyL in prostate cancer patients (OSPREY). *J Urol* 2021; 206(1): 61.

Consensus Statements / Guidelines

1. Lebastchi AH, George AK, Polascik TJ, Coleman J, de la Rosette J, Turkbey B, Wood BJ, **Gorin MA**, Sidana A, Ghai S, Tay KJ, Ward JF, Sanchez-Salas R, Muller BG, Malavaud B, Mozer P, Crouzet S, Choyke PL, Ukimura O, Rastinehad AR, Pinto PA. Standardized nomenclature and surveillance methodologies after focal therapy and partial gland ablation for localized prostate cancer: an international multidisciplinary consensus. *Eur Urol*; 2020; 78(3): 371-378.

Clinical Trial Protocols

1. Radwan N, Phillips R, Ross A, Rowe SP, **Gorin MA**, Antonarakis ES, Deville C, Greco S, Denmeade S, Paller C, Song DY, Diehn M, Wang H, Carducci M, Pienta KJ, Pomper MG, DeWeese TL, Dicker A, Eisenberger M, Tran PT. A phase II randomized trial of Observation versus stereotactic ablative Radiation for Oligometastatic prostate Cancer (ORIOLE). *BMC Cancer* 2017; 17(1): 453.
2. Hasan H, Deek MP, Phillips R, Hobbs RF, Malek R, Radwan N, Kiess AP, Dipasquale S, Huang J, Caldwell T, Leitzel J, Wendler D, Wang H, Thompson E, Powell J, Dudley S, Deville C, Greco SC, Song DY, DeWeese TL, **Gorin MA**, Rowe SP, Denmeade S, Markowski M, Antonarakis ES, Carducci MA, Eisenberger MA, Pomper MG, Pienta KJ, Paller CJ, Tran PT. A phase II randomized trial of Radium-223 dichloride and SABR Versus SABR for oligometastatic prostate cancer (RAVENS). *BMC Cancer* 2020; 20(1): 492.

Edited Textbooks

1. **Gorin MA**, Allaf ME, ed. *Diagnosis and Surgical Management of Renal Tumors*. 1st Edition. Springer International Publishing. 2019: 1-311.

Textbook Chapters

1. **Gorin MA**, Bivalacqua TJ. Prostate Cancer, Very Low Risk and Active Surveillance. In: Gomella LG, ed. *The 5-Minute Urology Consult*. 3rd Edition. Lippincott Williams & Wilkins. 2015: 342-343.

2. Pavlovich CP, **Gorin MA**, Pierorazio PM, Mullins JK. Pelvic Lymphadenectomy for Prostate & Bladder Cancer. In: Patel HRH, Mould T, Joseph JV, Delaney CP, ed. Pelvic Cancer Surgery: Modern Breakthroughs & Future Advances. 1st Edition. Springer. 2015: 69-78.
3. Meyer AR, Allaf ME, **Gorin MA**. Epidemiology and Risk Factors for Renal Cell Carcinoma. In Gorin MA, Allaf ME, ed. Diagnosis and Surgical Management of Renal Tumors. 1st Edition. Springer International Publishing. 2019: 1-11.
4. Rowe SP, Yin Y, **Gorin MA**. Imaging Renal Tumors. In Gorin MA, Allaf ME, ed. Diagnosis and Surgical Management of Renal Tumors. 1st Edition. Springer International Publishing. 2019: 55-69.
5. Liu JL, Allaf ME, **Gorin MA**. Adjuvant Therapy for High-Risk Renal Cell Carcinoma In Gorin MA, Allaf ME, ed. Diagnosis and Surgical Management of Renal Tumors. 1st Edition. Springer International Publishing. 2019: 263-269.
6. **Gorin MA**, Rowe SP. Genitourinary Tract Imaging: Basic Principles of Nuclear Medicine In Partin AW, Dmochowski RR, Kavoussi LR, Peters CA, ed. Campbell-Walsh-Wein Urology. 12th Edition. Elsevier; 2020: 91-100.
7. **Gorin MA**, Rowe SP. Genitourinary Tract Imaging: Basic Principles of Nuclear Medicine In Wein AJ, Kolon TF, Parin AW, Peters CA, Kavoussi LR, Dmochowski RR ed. Campbell-Walsh-Wein Urology Twelfth Edition Review. 3rd Edition. Elsevier; 2020: 15-16.
8. Gon LM, Celegatto IB, Bocos RG, **Gorin MA**, Reis LO. Basics of Biomarker Development and Interpretation In Lotan Y, Lawrentschuk N, Schalken J, Klotz L ed. ICUD-WUOF International Consultation: Molecular Biomarkers in Urologic Oncology. 1st Edition. 2020: 7-28.
9. **Gorin MA**, Allaf ME. Suprarenal (Adrenal) Gland In Standring S ed. Gray's Anatomy: The Anatomical Basis of Clinical Practice. 42nd Edition. Elsevier. 2020: 1239-1243.

Extramural Research Funding

- | | |
|-------------------|--|
| 07/01/14–06/30/15 | Development of a Novel Method for Detecting Circulating Tumor Cells in Patients with Renal Cell Carcinoma
AUA Urology Care Foundation
\$40,000
Role: PI, 80% Effort |
| 07/01/14–06/30/15 | Study of ^{99m} Tc-Sestamibi Single-photon Emission Computed Tomography (SPECT) Imaging for the Preoperative Diagnosis of Renal Oncocytoma
Nation Kidney Foundation of Maryland
\$10,000
Role: PI, 15% Effort |
| 03/28/16–3/27/19 | A Phase 3 Study to Evaluate the Safety and Efficacy of ^{99m} Tc-MIP-1404 SPECT/CT Imaging to Detect Clinically Significant Prostate Cancer in Men with Biopsy Proven Low-Grade Prostate Cancer who are Candidates for Active Surveillance (proSPECT-AS)
\$512,903
PI: Allaf
Role: Lead-Co-I, 5% Effort |
| 11/30/16–12/31/20 | Study of the Clinical Utility of PSMA Imaging in the Evaluation of Men with Prostate Cancer
Progenics Pharmaceuticals, Inc.
\$2,248,912
PI: Pienta
Role: Lead Co-I, 10% Effort |
| 11/07/18–11/06/19 | Prospective, Multi-Center Study of the ClariCore Optical Biopsy System in Patients Undergoing Prostate Biopsy for Prostate Tissue Classification Algorithm Development
\$41,600
PI: Gorin |

Role: PI, 2% Effort

- 01/16/19–06/30/20 A Phase 3, Multi-Center, Open-Label Study to Assess the Diagnostic Performance and Clinical Impact of 18F-DCFPyL PET/CT Imaging Results in Men with Suspected Recurrence of Prostate Cancer (CONDOR)
Progenics Pharmaceuticals, Inc.
\$507,468
Role: PI, 5% Effort
- 07/26/19–06/30/20 A Prospective Validation Study for Predicting the Likelihood of Grade Reclassification among Men on Active Surveillance (AS) for Low Risk Prostate Cancer (PCa) with a Pre-specified Four Kallikrein Panel (the 4Kast Study)
OPKO Health, Inc.
\$183,066
Role: PI, 2% Effort
- 09/17/19–07/31/21 Study of Percent Pattern 4 Prostate Cancer as Determined by Artificial Intelligence Networks to Predict Non-organ Confined Disease at Radical Prostatectomy
DeepBio, Inc.
\$80,168
Role: PI until 6/30/20, 2% Effort

Intramural Research Funding

- 01/01/14–06/30/15 Study of Clonal Heterogeneity among Prostate Cancer Circulating Tumor Cells Septembeard / The James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine
\$40,000
PI: Gorin
Role: PI, 5% Effort
- 09/01/18–06/30/20 A Phase II Study to Evaluate the Performance of PSMA-targeted 18F-DCFPyL PET/CT for the Detection of Clinically Significant Prostate Cancer in Men with an Elevated PSA
Patrick C. Walsh Research Fund, Johns Hopkins University School of Medicine
\$100,000
Role: PI, Effort 5% Effort
- 07/01/19–06/30/20 Prostate Cancer Precision Medicine Center of Excellence
Johns Hopkins inHealth, Johns Hopkins University School of Medicine
\$500,000
Role: PI, Effort 5% Effort

Invited Talks

- 11/06/15 “Novel Imaging Techniques in Renal Cell Carcinoma,” 14th International Kidney Cancer Symposium, Miami, FL
- 05/08/16 “Clinical Experience with PSMA-targeted 18F-DCFPyL PET/CT,” PyL Round Table (hosted by Progenics Pharmaceuticals), San Diego, CA
- 05/20/16 “PSMA-targeted PET/CT Imaging of Prostate Cancer,” 3rd Annual Sidney Kimmel Cancer Centers’ Prostate Cancer Amtrak Alliance Summit, Baltimore, MD
- 05/26/16 “Risk Stratification of Localized Renal Tumors Utilizing Molecular Imaging,” Urology Grand Rounds, Glickman Urological & Kidney Institute, Cleveland Clinic, Cleveland, OH
- 05/26/16 “Renal Mass Biopsy and Molecular Imaging,” Exchange Program on Renal Cell Carcinoma in a Hospital of Excellence, Cleveland, OH

- 06/24/16 “PSMA-targeted PET/CT Imaging of Prostate and Kidney Cancer,” 9th International Symposium on Focal Therapy and Imaging in Prostate and Kidney Cancer, Durham, NC
- 11/04/16 “Radical Prostatectomy and Pelvic Lymph Nodes Dissection for the OSPREY Trial,” OSPREY Trial Investigator Meeting, New York, NY
- 05/14/17 “PSMA-targeted PET Imaging of Prostate Cancer with Fluorinated Radiotracers,” Molecular Imaging in Urology: State of the Art and Future Directions Course at the American Urological Association 2017 Annual Meeting, Boston, MA
- 11/14/17 “PSMA-targeted Imaging of Prostate Cancer—A Urologist’s View PSMA-Directed Radionuclide Scientific Working Group Hosted by the Prostate Cancer Foundation,” New York, NY
- 11/29/17 “PSMA-targeted PET Imaging of Prostate Cancer with Fluorinated Radiotracers,” Society of Urologic Oncology (SUO) 18th Annual Meeting, Washington, DC
- 02/01/18 “Update on Image-guided Urology at the Brady,” Department of Urology Grand Rounds, Johns Hopkins University School of Medicine, Baltimore, MD
- 02/11/18 “PSMA-targeted Imaging of Prostate Cancer: Implications for Diagnosis and Management of Localized Disease,” 10th Annual International Symposium on Focal Therapy and Imaging in Prostate and Kidney Cancer, Noordwijk, The Netherlands
- 05/03/18 “Core Data Elements for the SPARED Registry,” SPARED Coordinated Registry Network (CRN) Think-Tank, United States Food & Drug Administration White Oak Campus, Silver Spring, MD
- 05/18/18 “The Role of Biopsy and Novel Imaging in the Evaluation Small Renal Masses,” Kidney Cancer Advocacy Hour at the American Urological Association 2018 Annual Meeting, San Francisco, CA
- 05/18/18 “Risk Stratification of Localized Renal Tumors Utilizing Molecular Imaging,” Course on Integrating Molecular Imaging into Urologic Oncology Clinical Practice: Current Approaches & Future Opportunities at the American Urological Association 2018 Annual Meeting, San Francisco, CA
- 05/19/18 “^{99m}Tc-sestamibi SPECT/CT for the Noninvasive Diagnosis of Benign Renal Oncocytomas and Hybrid Oncocytic/Chromophobe Tumors: Combined Data from Prospective Studies and Real-world Clinical Experience,” Early-Career Investigators Showcase at the American Urological Association 2018 Annual Meeting, San Francisco, CA
- 07/10/18 “Focal Therapy for Prostate Cancer: Lessons from Breast Surgeons,” SPARED Coordinated Registry Network (CRN) Think-Tank, United States Food & Drug Administration White Oak Campus, Silver Spring, MD
- 09/14/18 “PSMA-targeted Imaging of Prostate Cancer: Implications for Diagnosis and Management of Localized Disease,” World Molecular Imaging Congress, Seattle, WA
- 10/13/18 “Active Surveillance for Low-risk Prostate Cancer,” 14th Annual Meeting of the National Alliance of State Prostate Cancer Coalitions (NASPCC), Washington, D.C.
- 10/22/18 “Development of the Study of Prostate Ablation Related Energy Devices (SPARED) Registry,” MDEpiNet 9th Annual Meeting, United States Food & Drug Administration White Oak Campus, Silver Spring, MD
- 11/27/18 “Recent Advances in Prostate Biopsy: Where Do We Go from Here?” Urology Grand Rounds, Georgetown University, Washington, D.C.
- 02/28/19 “Update on the Prostate Cancer Program at the Brady,” Department of Urology Grand Rounds, Johns Hopkins University School of Medicine, Baltimore, MD
- 04/01/19 “Molecular Imaging of Prostate and Kidney Cancer,” Department of Urology Grand Rounds, New York Presbyterian / Weill Cornell Medical Center, New York, NY
- 04/18/19 “Molecular Imaging of Prostate Cancer,” Department of Urology Grand Rounds, University of Maryland Medical Center, Baltimore, MD
- 06/14/19 “Crossing the Divide from Transrectal to Transperineal Prostate Biopsy,” Department of Urology Grand Rounds, Vattikuti Urology Institute, Henry Ford Health System, Detroit, MI
- 06/14/19 “Molecular Imaging of Prostate and Kidney Cancer,” Department of Urology Grand Rounds, Vattikuti Urology Institute, Henry Ford Health System, Detroit, MI
- 09/05/18 “PET Imaging of Prostate Cancer,” PreCongress UroOncology Meeting, Campinas, Brazil

- 09/08/18 “Biomarkers for Improving the Accuracy of Prostate Cancer Screening,” XV Congresso Paulista de Urologia, São Paulo, Brazil
- 09/08/18 “Magnetic Resonance Imaging Prior to First Prostate Biopsy: Should We Consider It?” XV Congresso Paulista de Urologia, São Paulo, Brazil
- 09/08/18 “Arguments in Favor of Primary Retroperitoneal Lymph Node Dissection for Stage IIA/B Testis Cancer,” XV Congresso Paulista de Urologia, São Paulo, Brazil
- 09/02/18 “Energy Sources and Patient Selection for Prostate Cancer Ablation,” World Congress of Endourology, Paris, France
- 02/09/19 “PSMA-targeted Imaging in the Diagnosis and Management of Localized Prostate Cancer,” 11th Annual International Symposium on Focal Therapy and Imaging in Prostate and Kidney Cancer, Kyoto, Japan
- 04/05/19 “Crossing the Divide from Transrectal to Transperineal Prostate Biopsy,” Prostate Imaging & Focal Therapy Masterclass 2019, London, England
- 11/26/19 “The Winding Tale of Prostate Cancer Screening in the United States,” Department of Medicine Grand Rounds, Johns Hopkins Bayview Medical Center, Baltimore, MD
- 02/09/20 “Prostate Biopsy Using the PrecisionPoint Transperineal Access System,” 12th International Symposium on Focal Therapy and Imaging in Prostate and Kidney Cancer, Washington, D.C.
- 02/10/20 “Risk Stratification of Localized Renal Tumors Utilizing Molecular Imaging,” 12th International Symposium on Focal Therapy and Imaging in Prostate and Kidney Cancer, Washington, D.C.
- 04/15/20 “Crossing the Divide from Transrectal to Transperineal Prostate Biopsy,” Department of Urology, Universidade Estadual de Campinas, Campinas (UNICAMP), Brazil [via Google Hangouts]
- 04/22/20 “Crossing the Divide from Transrectal to Transperineal Prostate Biopsy,” Department of Urology, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil [via Google Hangouts]
- 10/24/20 “Biopsia por fusión transperineal con el PrecisionPoint Transperineal Access System,” XXXIX Congreso de la Confederacion Americana de Urologia, Guayaquil, Ecuador [via Skype]
- 11/04/20 “Crossing the Divide from Transrectal to Transperineal Prostate Biopsy,” Department of Urology Grand Rounds, University of Pittsburgh School of Medicine, Pittsburgh, PA [via Teams]
- 11/11/20 “Ponto e contra ponto: biópsia próstata (transrectal vs. transperineal),” XVI Congresso Paulista de Urologia [via Shocklogic platform]
- 02/02/21 “Transperineal Prostate Biopsy Under Local Anesthesia,” Department of Urology Grand Rounds, NYU Langone Hospital–Long Island, Mineola, NY [via Webex]
- 02/18/21 “Crossing the Divide from Transrectal to Transperineal Prostate Biopsy,” Department of Urology Grand Rounds, Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA [via Zoom]
- 03/24/21 “Crossing the Divide from Transrectal to Transperineal Prostate Biopsy,” Department of Urology Grand Rounds, Icahn School of Medicine at Mount Sinai, New York, NY [via Zoom]
- 04/05/21 “Crossing the Divide from Transrectal to Transperineal Prostate Biopsy,” Department of Urology Grand Rounds, King Hussain Cancer Center, Amman Jordan [via Teams]
- 06/15/21 “Risk Stratification of Localized Renal Tumors with Molecular Imaging,” Course on Integrating Molecular Imaging into Urologic Oncology Clinical Practice: Current Approaches & Future Opportunities, AUA2021 Summer School Live Webinar Course Series [via Zoom]
- 06/23/21 “Crossing the Divide from Transrectal to Transperineal Prostate Biopsy,” Rutgers Robert Wood Johnson Medical School, Department of Surgery / Division of Urology Grand Rounds, New Brunswick, NJ [via Zoom]
- 07/12/21 “PSMA-targeted PET Imaging of Prostate Cancer–A Primer for Urologists.” American Urological Association 2021 Annual Meeting [via Zoom]

07/14/21 “PSMA-targeted PET Imaging of Prostate Cancer—A Primer for Urologists.” Department of Urology Grand Rounds, University of Pittsburgh School of Medicine, Pittsburgh, PA [via Teams]

Industry Sponsored Talks

06/10/20 “Role of MR-targeted prostate biopsy in diagnosis and impact on treatment: techniques, technology, and outcomes” Sponsored by KOELIS [via Zoom]
06/16/20 “Crossing the Divide from Transrectal to Transperineal Prostate Biopsy,” Grand Rounds in Urology Sponsored by Perineologic [via Zoom]
01/28/21 “Elevating Prostate Patient Care with Transperineal Fusion Biopsy,” Sponsored by BK Medical [via WebEx]
09/28/21 “Crossing the Divide from Transrectal to Transperineal Prostate Biopsy,” New Jersey Urology Educational Meeting, West Orange, NJ

Inventions, Patents, Copyrights

04/21/16 Co-inventor, Devices and methods for magnetic isolation and analysis of rare cells, United States Provision Patent Application No. 62/325,629
12/08/20 Co-inventor, Nuclear imaging and radiotherapeutic agents targeting carbonic anhydrase IX and uses thereof, United States Patent US10857246B2, Expires 06/01/2036.
01/17/22 Co-inventor, Hydrodissection-reliant endoscopic vein harvesting system, United States Provision Patent Application No. US 63/300,206

Editorial Board Appointments

2017–2018 Editorial Board Member, *British Journal of Urology International*
2017–Present Consulting Editor, *Urology*
2017–Present Editorial Board Member, *World Journal of Urology*
2018–2020 Consulting Editor (Oncology), *British Journal of Urology International*
2018–Present Consulting Editor, *Urologic Oncology: Seminars and Original Investigations*
2019–Present Diagnostic Imaging Editor, *Actas Urológicas Españolas*
2020–Present Editorial Board Member, *British Journal of Urology International*

Journal Peer Review

Ad hoc reviewer for the following journals: *Annals of Surgical Oncology*, *Asian Journal of Andrology*, *BMC Cancer*, *British Journal of Urology International*, *Case Reports in Urology*, *Central European Journal of Urology*, *Clinical Genitourinary Cancer*, *European Journal of Nuclear Medicine and Molecular Urology*, *European Urology Focus*, *International Journal of Urology*, *Journal of Clinical Oncology*, *Medical and Surgical Urology*, *Nature Reviews Urology*, *PLoS One*, *Postgraduate Medicine*, *Prostate Cancer and Prostatic Diseases*, *The Journal of Urology*, *Urology*, *Urologic Oncology*, *World Journal of Urology*

Other Peer Review

2011 Meeting Abstract Reviewer, 26th Annual Meeting of the Engineering & Urology Society
2012 Meeting Abstract Reviewer, 27th Annual Meeting of the Engineering & Urology Society
2015 Meeting Abstract Reviewer, 30th Annual Meeting of the Engineering & Urology Society
2016 Meeting Abstract Reviewer, 31st Annual Meeting of the Engineering & Urology Society
2017 Meeting Abstract Reviewer, 32nd Annual Meeting of the Engineering & Urology Society

Advisory Committees, Review Groups, Study Sections

2019 Grant Reviewer, Patrick C. Walsh Research Fund, Johns Hopkins University School of Medicine

Conference Organization

2020 Scientific Committee Member, 12th International Symposium on Focal Therapy and Imaging in Prostate and Kidney Cancer, Washington DC

CLINICAL ACTIVITIES

Clinical Service Responsibilities

2017–2020	Attending Physician / on-call urologist at Johns Hopkins Hospital, Johns Hopkins Bayview Medical Center, and Johns Hopkins Health Care & Surgery Center—Green Spring Station, Baltimore, MD
2017–2020	Co-Director of the Prostate Cancer Multidisciplinary Clinic, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Hospital, Baltimore, MD
2020–Present	Associate Urologist, Urology Associates, Cumberland, MD
2020–Present	Staff Physician / on-call urologist at UPMC Western Maryland, Cumberland, MD

Clinical Program Building/Leadership

2016	Clinical implementation of ^{99m} Tc-sestamibi SPECT/CT imaging of renal tumors, Johns Hopkins Hospital and Johns Hopkins Bayview Medical Center, Baltimore, MD
2017	Development and clinical implementation of an Epic-based workflow for performing and documenting point-of-care urologic ultrasound exams, Johns Hopkins Outpatient Center, Baltimore, MD
2017	Clinical implementation of transperineal prostate biopsy, Johns Hopkins Outpatient Center, Baltimore, MD
2019	Clinical implementation of MRI-guided transperineal prostate biopsy using the KOELIS Trinity biopsy platform, Johns Hopkins Green Spring Station Pavilion III Ambulatory Surgical Center, Lutherville, MD
2019	Clinical implementation of SpaceOAR for patients undergoing radiation therapy for prostate cancer, Urology Clinic, Johns Hopkins Green Spring Station Pavilion III, Lutherville, MD
2019	Clinical implementation of MRI-guided focal cryoablation for the treatment of prostate cancer using the bkFusion platform, Johns Hopkins Hospital, Baltimore, MD
2020	Clinical implementation of MRI-guided transperineal prostate biopsy using the KOELIS Trinity and bkFusion biopsy platforms, Urology Associates, Cumberland, MD
2020	Clinical implementation of MRI-guided focal cryoablation for the treatment of prostate cancer using the KOELIS Trinity Platform, Urology Associates, Cumberland, MD
2021	Clinical implementation of Holmium Laser Enucleation of the Prostate, Urology Associates, Cumberland, MD

Case Demonstration

01/10/18	Peter Caputo, M.D., Urologist at Granger Medical Clinic, Salt Lake City, UT, Demonstrated in-office transperineal prostate biopsy at the Johns Hopkins Outpatient Center, Baltimore, MD
01/10/18	Flávio Ordones, M.D., Urologist in São Paulo, Brazil, Demonstrated in-office transperineal prostate biopsy at the Johns Hopkins Outpatient Center, Baltimore, MD
07/26/18	Jim C. Hu, M.D., Professor of Urology at Weil Cornell Medical Center, New York, NY, Demonstrated in-office transperineal prostate biopsy at the Johns Hopkins Outpatient Center, Baltimore, MD
07/10/19	Letecia Ruiz, M.D., Urologist at Hospital Punta Pacifica, Panama City, Panama, Demonstrated transperineal prostate biopsy and focal cryoablation of the prostate at the Johns Hopkins Hospital, Baltimore, MD
08/30/19	Jose Quesada-Olarte, M.D., PGY-4 Urology Resident at Hospital Universitario La Paz, Madrid, Spain, Demonstrated robotic radical prostatectomy at the Johns Hopkins Hospital, Baltimore, MD

- 09/14/19 Adam Kinnaird, M.D., Ph.D., Fellow in Focal Therapy and Targeted Biopsy at the University of California Los Angeles, Los Angeles, CA, Demonstrated transperineal prostate biopsy under local anesthesia, Johns Hopkins Pavilion III Ambulatory Surgical Center, Lutherville, MD
- 01/24/20 Quoc-Dien Trinh, M.D., Associate Professor of Surgery & Mark A. Preston, M.D., M.P.H., Assistant Professor of Surgery, Brigham and Women's Hospital, Harvard Medical School, Demonstrated MRI-guided transperineal prostate biopsy under local anesthesia, Johns Hopkins Pavilion III Ambulatory Surgical Center, Lutherville, MD
- 10/27/20 Benjamin Davies, M.D., Professor of Urology, University of Pittsburg, Demonstrated transperineal prostate biopsy and focal cryoablation of the prostate at the Urology Associates Ambulatory Surgical Center, Cumberland, MD
- 05/21/21 Fernando Kim, MD, Chief Emeritus of Urology at Denver Health Medical Center, Professor of Surgery/Urology at the University of Colorado at Denver, Demonstrated transperineal prostate biopsy and focal cryoablation of the prostate at the Urology Associates Ambulatory Surgical Center, Cumberland, MD

Case Proctoring

- 05/21/20 Proctored Jeffrey Becker, M.D. performing transperineal prostate biopsy procedures, New Jersey Urology, LLC, Mr. Laurel, NJ
- 06/22/20 Proctored Aaron Laviana, M.D. and Daniel Barocas M.D., M.P.H. performing transperineal prostate biopsy procedures, Vanderbilt University Medical Center, Nashville, TN
- 08/21/20 Proctored Daniel J. Cole, M.D. and Amir Toussi, M.D. performing transperineal prostate biopsy procedures, UPMC Passavant, Pittsburg, PA
- 09/03/20 Proctored George Stackhouse, M.D. and Jonah Murdock, M.D., Ph.D. performing transperineal prostate biopsy procedures, Washington DC VA Medical Center, Washington, DC
- 10/09/20 Proctored Meni Menon, M.D., Akshay Sood, M.D., and Lee Baumgarten, M.D. performing transperineal prostate biopsy procedures, Henry Ford Medical Center – Fairlane, Dearborn, MI
- 10/20/20 Proctored Costas Lallas, M.D., Thenu Chandrasekar, M.D., Mark Mann, M.D., Christopher Caputo, M.D., May Jean Counsilman, M.D., and Radhika Ragam, M.D. performing transperineal prostate biopsy procedures, Thomas Jefferson University Hospital, Philadelphia, PA
- 11/13/20 Proctored Aaron Laviana, M.D. performing transperineal prostate biopsy procedures, Dell Seton Medical Center, Austin, TX
- 01/19/21 Proctored David Green, M.D. performing transperineal prostate biopsy procedures, Weill Cornell New York-Presbyterian Queens, Queens, NY
- 01/20/21 Proctored Behfar Ehdaie, M.D., M.P.H. performing transperineal prostate biopsy procedures, Memorial Sloan Kettering Cancer Center, New York, NY
- 01/21/21 Proctored Anthony Corcoran, M.D. performing transperineal prostate biopsy procedures, NYU Langone Hospital—Long Island, Mineola, NY
- 03/23/21 Proctored Benjamin Davies, M.D. and Bruce L Jacobs, M.D., M.P.H. performing transperineal prostate biopsy procedures, UPMC Shadyside, Pittsburgh, PA
- 04/19/21 Proctored Saum Ghodoussipour, M.D. performing transperineal prostate biopsy procedures, Ambulatory Surgical Pavilion at Robert Wood Johnson, New Brunswick, NJ
- 06/07/21 Proctored Justin Emtage, M.D. performing transperineal prostate biopsy procedures, AdventHealth Winter Park, Winter Park, FL
- 06/21/21 Proctored David Green, M.D. and Gerald Wong, M.D. performing transperineal prostate biopsy procedures, Weill Cornell New York-Presbyterian Queens, Queens, NY
- 07/02/21 Proctored Evan Kovac, M.D. performing transperineal prostate biopsy procedures using PPTAS and KOELIS Trinity, Bronx, NY
- 07/30/21 Proctored Timothy D. McClure, M.D. performing transperineal prostate biopsy procedures, New York-Presbyterian/Weill Cornell Medical Center, New York, NY

- 11/20/21 Proctored Marc Bjurlin, D.O. performing transperineal prostate biopsy procedures, University of North Carolina Medical Center, Chapel Hill, NC
- 12/13/21 Proctored Christopher Weight, M.D. performing transperineal prostate biopsy procedures, Cleveland Clinic, Cleveland, OH

Patient Reviews

- Healthgrades: <https://www.healthgrades.com/physician/dr-michael-gorin-3pk9d>
- Vitals: <https://www.vitals.com/doctors/1tzmf7/michael-gorin>
- WebMD: <https://doctor.webmd.com/doctor/michael-gorin-2883ac4c-dec5-11e7-9f4c-005056a225bf-overview>

EDUCATIONAL ACTIVITIES

Classroom Instruction

- 07/25/17 “Overview of Neurourology,” Urology Residents Teaching Conference, Johns Hopkins University School of Medicine, Baltimore, MD
- 08/21/17 “Obstructive Nephropathy,” Nephrology Fellows Teaching Conference, Johns Hopkins University School of Medicine, Baltimore, MD
- 09/26/17 “Urolithiasis,” Urology Residents Teaching Conference, Johns Hopkins University School of Medicine, Baltimore, MD
- 12/14/17 “Lower Urinary Tract Symptoms in Men,” Urology Residents Teaching Conference, Johns Hopkins University School of Medicine, Baltimore, MD
- 01/30/18 “Sexual Transmitted Infections and Urethral Stricture Disease,” Urology Residents Teaching Conference, Johns Hopkins University School of Medicine, Baltimore, MD
- 03/13/18 “Renal Cell Carcinoma – How the Genetic Basis Informs Therapeutic Strategies,” Urology Residents Teaching Conference, Johns Hopkins University School of Medicine, Baltimore, MD
- 06/26/18 “Basics of Renal Scintigraphy,” Urology Residents Teaching Conference, Johns Hopkins University School of Medicine, Baltimore, MD
- 07/17/18 “Basic of Neurourology,” Urology Residents Teaching Conference, Johns Hopkins University School of Medicine, Baltimore, MD
- 06/30/18 “Prostate Cancer Screening & Management of Early Stage Disease” Radiation Oncology Residents Teaching Conference, Johns Hopkins University School of Medicine, Baltimore, MD
- 08/13/18 “Obstructive Nephropathy,” Nephrology Fellows Teaching Conference, Johns Hopkins University School of Medicine, Baltimore, MD
- 09/10/18 “Urolithiasis,” Urology Residents Teaching Conference, Johns Hopkins University School of Medicine, Baltimore, MD
- 09/24/18 “Pathophysiology of Kidney Stone Disease,” Second Year Medical Student Curriculum, Johns Hopkins University School of Medicine, Baltimore, MD
- 09/25/18 “Adrenal Physiology and Management of Adrenal Incidentalomas,” Urology Residents Teaching Conference, Johns Hopkins University School of Medicine, Baltimore, MD
- 10/04/18 “Difficult Cases in Endourology,” Grand Rounds, Department of Urology, Johns Hopkins University School of Medicine, Baltimore, MD
- 11/30/18 “Difficult Cases in Endourology,” Grand Rounds, Department of Urology, Johns Hopkins University School of Medicine, Baltimore, MD
- 03/05/19 “Diagnostic Test Statistics and PSA Screening,” Urology Residents Teaching Conference, Johns Hopkins University School of Medicine, Baltimore, MD
- 03/28/19 “Difficult Cases in Endourology,” Grand Rounds, Department of Urology, Johns Hopkins University School of Medicine, Baltimore, MD

- 05/07/19 “Surgical Management of Benign Prostatic Hyperplasia” Urology Residents Teaching Conference, Johns Hopkins University School of Medicine, Baltimore, MD
- 08/05/19 “Neurourology for Dummies,” Urology Residents Teaching Conference, Johns Hopkins University School of Medicine, Baltimore, MD
- 08/22/19 “Difficult Cases in Endourology,” Grand Rounds, Department of Urology, Johns Hopkins University School of Medicine, Baltimore, MD
- 09/03/19 “Practice In-Service Question Review—Pediatric Urology,” Urology Residents Teaching Conference, Johns Hopkins University School of Medicine, Baltimore, MD
- 09/07/19 Live Case Moderator, Urologic Residents and Fellows Preceptorship Program in Robotic Surgery, Sponsored by the Society of Urological Robotic Surgeons, Baltimore, MD
- 09/11/19 “Prostate Cancer Screening & Management of Early Stage Disease” Radiation Oncology Residents Teaching Conference, Johns Hopkins University School of Medicine, Baltimore, MD
- 09/25/19 “Pathophysiology of Kidney Stone Disease,” Second Year Medical Student Curriculum, Johns Hopkins University School of Medicine, Baltimore, MD
- 09/22/21 “Partial Gland Treatment of Prostate Cancer—A Primer for Urology Residents,” Urology Resident Teaching Conference, Icahn School of Medicine at Mount Sinai, New York, NY [via Zoom]

CME Instruction

- 10/09/15 “Data from The Johns Hopkins Renal Mass Registry,” 1st Annual DelMarVaDC Regional Cancer Registrars Educational Meeting, Baltimore, MD
- 09/16/16 “Biomarkers for Prostate Cancer Screening & Evaluation of Early Stage Disease,” 2016 Uro-Track CME, Baltimore, MD
- 09/17/16 “Risk Stratification of Localized Renal Tumors Utilizing Molecular Imaging,” 2016 Uro-Track CME, Baltimore, MD
- 11/14/18 “Update on Prostate Cancer Screening for Primary Care Providers,” Johns Hopkins Community Physicians 19th Annual Provider Retreat, Baltimore, MD
- 03/02/19 “Recent Advances in Prostate Biopsy: Where Do We Go from Here?” Utah Urological Society Annual CME Symposium, Salt Lake City, UT [via Skype]
- 10/03/19 “Recent Advances in Imaging Prostate Cancer,” 2019 Uro-Track CME, Baltimore, MD
- 10/05/19 “Active Surveillance of Favorable Risk Prostate Cancer,” 2019 Uro-Track CME, Baltimore, MD
- 11/13/19 “Prostate Cancer Screening in 2019,” Johns Hopkins Community Physicians 20th Annual Provider Retreat, Baltimore, MD
- 10/03/20 “Freehand Transperineal Prostate Biopsy,” In-Office Transperineal Interventions: Live Interactive Breakout Session, Frontiers in Oncologic Prostate Care and Ablative Local Therapy (FOCAL 2020) Course [via Zoom]
- 10/03/20 “Planning and Delivery of Focal Cryoablation of the Prostate,” Fusion Guided Ablation: Live Interactive Breakout Session, Frontiers in Oncologic Prostate Care and Ablative Local Therapy (FOCAL 2020) Course [via Zoom]
- 11/11/20 “Biomarkers for the Diagnosis of Prostate Cancer,” 2020 Virtual Perspectives in Urology: Point Counterpoint CME Symposium [via Zoom]
- 12/12/20 “Freehand Transperineal Prostate Biopsy Under Local Anesthesia,” 2020 Southwest Prostate Cancer Symposium [via Zoom]
- 12/12/20 “Prostate Biopsy using the PrecisionPoint Transperineal Access System,” Virtual Hands-on Training, 2020 Southwest Prostate Cancer Symposium [via Zoom]
- 12/12/20 “MRI-guided Transperineal Prostate Biopsy with the KOELIS Trinity Platform,” Virtual Hands-on Training, 2020 Southwest Prostate Cancer Symposium [via Zoom]
- 07/16/21 “Transperineal Prostate Biopsy: A New Standard of Care?” 31st Annual International Prostate Cancer Update, Snowbird, UT [via Zoom]
- 07/16/21 “Recent Innovations in MRI-Guided Prostate Biopsy,” 31st Annual International Prostate Cancer Update, Snowbird, UT [via Zoom]

12/09/21 “A Primer on Transperineal Prostate Biopsy,” 25th Southwest Prostate Cancer Symposium, Scottsdale, AZ [via Zoom]

Visiting Professorships

06/14/19–06/15/19 Visiting Professor and Urology Residency/Fellowship Graduation Speaker, Vattikuti Urology Institute, Henry Ford Health System, Detroit, MI

Workshops/Consensus Meetings

07/22/16 Participant, HIFU Registry Think-Tank, United States Food & Drug Administration White Oak Campus, Silver Spring, MD

09/25/17 Participant, SPARED Coordinated Registry Network (CRN) Think-Tank, United States Food & Drug Administration White Oak Campus, Silver Spring, MD

05/03/18 Participant, SPARED Coordinated Registry Network (CRN) Think-Tank, United States Food & Drug Administration White Oak Campus. Silver Spring, MD

07/10/18 Participant, SPARED Coordinated Registry Network (CRN) Think-Tank, United States Food & Drug Administration White Oak Campus. Silver Spring, MD

02/09/19 Participant, Consensus Meeting on Follow-up after Focal Therapy for Prostate Cancer, 11th International Symposium on Focal Therapy and Imaging of Prostate and Kidney Cancer, Kyoto, Japan

Mentorship

2016–2017 Scott Campbell, Medical Student at Johns Hopkins University School of Medicine, Mentorship in Clinical Research, Currently a Urology Resident at Duke University

2018–2019 Michael Zimmerman, Research Assistant, Mentorship in Clinical Research, Currently a Medical Student at Duke University School of Medicine

2016–2019 Heather Chalfin, M.D., Urology Resident at Johns Hopkins University School of Medicine, Mentorship in Clinical and Translational Research, Currently a staff urologist at Frederick Health Medical Group - Urology Specialists

2017–2020 Alexa Meyer, M.D., Urology Resident at Johns Hopkins University School of Medicine, Mentorship in Clinical Research, Currently an endourology fellow at Lenox Hill

2020–Present Spyridon Basourakos, M.D., Urology Resident at Weill Cornell Medical College / New York Presbyterian Hospital, Mentorship in Clinical Research

2021 Akshay Sood, M.D., Fellow in Robotic Surgery at the Vattikuti Urology Institute, Henry Ford Health System, Mentorship in Clinical Research, Current a urologic oncology fellow at MD Anderson Cancer Center

2021 Mohit Butaney, MB BCH, Research Fellow at the Vattikuti Urology Institute, Henry Ford Health System, Mentorship in Clinical Research

2021–Present Ralph Grauer, M.D., M.B.A., Research Fellow, Department of Urology, Icahn School of Medicine at Mount Sinai, Mentorship in Clinical Research

2021–Present Ross Knaub, Medical Student, Lake Erie College of Osteopathic Medicine, Clinical Preceptor and Mentorship in Clinical Research